ciprofloxacin and Urinary Tract Infections studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.

Research Excerpts

Excerpt	Relevance	Reference
"We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women."	9.51	Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. ( Bonten, MJM; Branger, J; Geerlings, SE; Hassing, RJ; Hoepelman, AIM; Ketels, T; Koldewijn, EL; Koster, A; Kuiper, S; Ten Doesschate, T; van den Bijllaardt, W; van der Bij, AK; van Mens, SP; van Nieuwkoop, C; van Werkhoven, CH, 2022)
" This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract infection and/or pyelonephritis."	9.27	Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections. ( Bentley, C; Dalhoff, A; Fischer, C; Lückermann, M; Naber, K; Nowicki, M; Vente, A; Wagenlehner, F; Wohlert, S, 2018)
"The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs)."	9.14	Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections. ( Di Vito, C; Fusco, F; Imbimbo, C; Lotti, T; Mirone, V; Taglialatela, D; Verze, P, 2009)
"Furagin (a nitrofurantoin analogue) has the same efficacy in treating acute cystitis as ciprofloxacin, however the duration of therapy is longer."	9.13	Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. ( Borkowski, A; Dybowski, B; Gromadzka-Ostrowska, J; Jabłońska, O; Radziszewski, P, 2008)
"A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)."	9.13	A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008)
"To determine the efficacy of prophylactic ciprofloxacin in preventing urinary tract infections caused by urodynamic study (UDS)."	9.12	Effectiveness of ciprofloxacin prophylaxis in preventing bacteriuria caused by urodynamic study: a blind, randomized study of 192 patients. ( Kale, M; Kartal, ED; Kiremitci, A; Meric, H; Usluer, G; Yenilmez, A, 2006)
"To evaluate whether 1 week of ciprofloxacin before percutaneous nephrolithotomy (PCNL) in patients with stones of > or = 20 mm or pelvicalyceal dilatation, reduces urosepsis, as we previously reported that such patients have four times the risk of urosepsis after PCNL."	9.12	One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. ( Mariappan, P; Moussa, SA; Smith, G; Tolley, DA, 2006)
"This report focuses on the role of Pseudomonas aeruginosa in complicated urinary tract infections in a prospective, open-label, multicenter study designed to evaluate the safety and efficacy of extended-release ciprofloxacin (ciprofloxacin XR) 1000 mg once daily for 7-14 days for the treatment of complicated urinary tract infections."	9.12	Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa. ( Benson, A; Haverstock, D; Herrington, J; Perroncel, R; Pertel, P; Saltzstein, D; Wachs, B, 2007)
"We assessed the efficacy and safety of 1,000 mg extended release ciprofloxacin orally once daily vs conventional 500 mg ciprofloxacin orally twice daily, each for 7 to 14 days, in patients with a complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis (AUP)."	9.11	Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. ( Church, DA; Klimberg, IW; Kowalsky, SF; Nicolle, LE; Song, J; Talan, DA, 2004)
"These data indicate that a 3 day treatment with ciprofloxacin is at least as clinically and bacteriologically effective as 7 day treatments with trimethoprim/sulfamethoxazole and norfloxacin for uncomplicated lower urinary tract infections."	9.11	Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. ( Amábile-Cuevas, CF; Arredondo-García, JL; Cardeñosa-Guerra, O; Corral, M; Costa, A; Figueroa-Damián, R; Hernández-Oliva, GM; Jáuregui, A; Merlos, RM; Olguín, J; Ríos-Fabra, A; Rosas, A, 2004)
"The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs)."	9.11	Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. ( Carmignani, G; De Rose, AF; Dionisio, P; Olivieri, L; Rosignoli, MT; Salvatori, E, 2005)
"This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis."	9.10	A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. ( Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY, 2002)
"Ciprofloxacin is considered to be the standard treatment for patients with complicated urinary tract infections (UTI)."	9.09	Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group. ( Krcmery, S; Naber, KG, 1999)
"The efficacy and safety of lomefloxacin 400 mg daily in the treatment of complicated urinary tract infections were confirmed in a randomized multicenter study that enrolled 294 patients from 16 centers in Italy."	9.08	Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. ( Bartoletti, R; Pisani, E; Rizzo, M; Trinchieri, A, 1996)
"We evaluated and compared the efficacy of post-intercourse and daily oral ciprofloxacin prophylaxis against recurrent lower urinary tract infections in 135 sexually active premenopausal women."	9.08	Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. ( Asbach, HW; Gerharz, E; Melekos, MD; Naber, KG; Weingaertner, K; Zarakovitis, IE, 1997)
"We compared the efficacy and safety of once-daily fleroxacin and twice-daily ciprofloxacin in patients with complicated urinary tract infections."	9.08	Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. ( Bischoff, W; Frankenschmidt, A; Kullmann, K; Naber, KG, 1997)
"In this large, multicenter, double-blind clinical trial, 404 women with acute, uncomplicated urinary tract infections (UTI) were randomized to receive temafloxacin 400 mg once daily for 3 days, or ciprofloxacin 250 mg twice daily for 7 days."	9.07	Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. ( Philip, E; Stein, GE, 1992)
"The efficacy and safety of two fluoroquinolone antimicrobial agents, lomefloxacin and ciprofloxacin, were compared in a randomized, investigator-blinded, multiple-dose study that enrolled 150 adult outpatients with complicated or recurrent urinary tract infections."	9.07	A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. ( Cox, CE, 1992)
"In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration."	9.07	[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991)
"Intravenous ciprofloxacin and ceftazidime were compared for efficacy in the treatment of nosocomial pneumonia and urinary tract infection (UTI)."	9.07	Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. ( Billeter, M; Dempsey, RJ; Hatton, J; Rapp, RP; Tibbs, PA; Young, AB, 1991)
"In a double-blind randomized trial, we evaluated the efficacy and safety of three oral dosage regimens of fleroxacin, a new fluoroquinolone, once daily in 62 patients for the treatment of complicated urinary tract infections."	9.06	Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections. ( Hoepelman, AI; Verhoef, J; Wolfhagen, MJ, 1990)
"Urinary tract infections in 32 patients were treated with 250 mg of ciprofloxacin twice daily for seven to eight days."	9.06	Treatment of urinary tract infections with ciprofloxacin. ( Bonamini, A; Curotto, A; Giberti, C; Martorana, G; Oneto, F; Pizzorno, R; Soro, O, 1988)
"In a prospective, randomized, double-blind study, the effect of ciprofloxacin (250 mg orally, twice daily) was compared with that of trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally, twice daily) on 45 patients with complicated urinary tract infections."	9.06	Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. ( Allais, JM; Bittner, MJ; Cuevas, TA; Mellencamp, MA; Preheim, LC; Roccaforte, JS, 1988)
"Ofloxacin was administered to 18 patients and ciprofloxacin to 17 patients suffering from acute or chronic complicated urinary tract infections."	9.06	Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. ( Kromann-Andersen, B; Larsen, V; Pers, C; Rasmussen, F; Sommer, P, 1986)
"Two single-dose regimens of ciprofloxacin, 100 and 250 mg, were compared in the treatment of uncomplicated urinary tract infections in women."	9.06	Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. ( Flepp, M; Garlando, F; Lüthy, R; Meier, B; Rietiker, S; Täuber, MG, 1987)
"In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections."	9.06	Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. ( Alpert, ML; Citron, DM; Ginsberg, BP; Goldstein, EJ; Greenway, FL; Kahn, RM, 1987)
"Ciprofloxacin treatment of urinary tract infections in 23 patients (16 with and seven without urorenal abnormalities) was compared with beta-lactam antibiotic therapy given orally to 10 comparable patients."	9.06	Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. ( Daikos, GL; Jackson, GG; Kathpalia, SB; Lolans, VT; Sharifi, R, 1987)
"The effectiveness and safety of ciprofloxacin, a new quinolone antibiotic, were prospectively evaluated in the treatment of patients with complicated urinary tract infections caused by gram-negative organisms resistant to trimethoprim/sulfamethoxazole."	9.06	Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. ( Bittner, MJ; Cuevas, TA; Mellencamp, MA; Preheim, LC; Roccaforte, JS, 1987)
"2 years), with urinary tract infections caused by Pseudomonas species or other organisms resistant to trimethoprim-sulfamethoxazole were treated with 500 mg of orally administered ciprofloxacin every 12 hours."	9.06	Oral ciprofloxacin in resistant urinary tract infections. ( Andriole, VT; Berenson, CS; Greco, TP; Mangi, RJ; Ryan, JL; Sims, M; Thornton, GF, 1987)
"Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)."	8.85	Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. ( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009)
"These cases illustrate that cefoxitin is an interesting alternative to carbapenems, even in severe infections such as endocarditis."	8.12	Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis. ( Courtois, R; Danneels, P; Dubée, V; Eveillard, M; Kempf, M; Mahieu, R; Quinqueneau, C; Rihet, C; Vannier, C, 2022)
"Antimicrobial resistance to ciprofloxacin is rising worldwide, especially in bacteria causing urinary tract infections (UTIs)."	7.85	Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. ( de Visser, H; Goessens, WH; Hofman, A; Kiefte-de Jong, JC; Mulder, M; Stricker, BH; Verbon, A, 2017)
"The antibiotic nitrofurantoin is commonly used to treat uncomplicated urinary tract infections."	7.81	Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. ( Gandhi, S; Garg, AX; Jain, AK; Liu, AR; McArthur, E; Moist, L; Singh, N; Sood, MM, 2015)
"The aims of this study were to investigate the prevalence of qnrA, qnrB, and qnrS determinants and their molecular characteristics in ciprofloxacin-resistant isolates of Escherichia coli and Klebsiella pneumoniae from urinary tract infections (UTI) in Korea."	7.74	High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. ( Chang, CL; Jung, HJ; Kim, HR; Lee, JN; Lee, JY; Shin, JH, 2008)
"Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E."	7.74	In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007)
"To detect if isolates susceptible to quinolones already carry mutations in the gyrA and parC genes, we selected 12 ciprofloxacin-susceptible Escherichia coli strains collected from patients with urinary tract infections in Latin America in 1998, as part of ongoing SENTRY Antimicrobial Surveillance Program."	7.70	Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. ( Gales, AC; Gordon, KA; Jones, RN; Pfaller, MA; Wilke, WW, 2000)
"Minimum inhibitory concentrations (MICs) of gatifloxacin were compared with those of gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin using an agar dilution method for 400 uropathogens cultured from the urine of urological patients with complicated and/or hospital-acquired urinary tract infections (UTI)."	7.70	In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. ( Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W, 2000)
"An attempt has been undertaken to evaluate the aetiology of urinary tract infections in a large group of patients and to determine the resistance to ciprofloxacin during therapy, and the efficacy of the drug in treating of urinary tract infections."	7.69	[Microbiological evaluation of ciprofloxacin efficacy for treatment of urinary tract infections]. ( Denys, A; Kalisz, J; Rogowska-Kalisz, A; Rusinek, A; Szczerba, W, 1996)
"As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study."	7.68	Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993)
"In this retrospective study of 30 patients with urinary tract infections, a drug usage evaluation indicated that 60% of the patient population sampled were appropriately switched to ciprofloxacin from IV antimicrobial agents; inappropriate use was identified in 40%."	7.68	DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients. ( Dydek, GJ; Matthews, SJ; Souney, PF, 1992)
"In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week."	7.67	Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. ( Chysky, V; Dammekens, H; Van Poppel, H; Wegge, M, 1986)
"In this study the in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections was examined."	7.67	[The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections]. ( Tunçkanat, F; Yuluğ, N, 1988)
"Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa."	7.67	Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986)
"Eighty-three patients with serious urinary tract infections were treated with oral ciprofloxacin."	7.67	Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections. ( Fass, RJ, 1987)
"The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)."	7.67	Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986)
"The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial."	6.71	Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004)
"The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)."	6.71	Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004)
"Ciprofloxacin is an effective and safe treatment for uncomplicated urinary tract infection in general practice."	6.66	Ciprofloxacin versus amoxycillin/clavulanic acid in the treatment of urinary tract infections in general practice. ( Abbas, AM; Chandra, V; Dongaonkar, PP; Goel, PK; Kacker, P; Patel, NA; Shrivastava, OP; Thakkar, B; Tillotson, GS, 1989)
"Ciprofloxacin was given orally at different dose regimens: 500 mg b."	6.66	Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988)
"Ciprofloxacin has proved to be superior to cefalexin in the treatment of lower UTI."	6.66	Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study. ( Jórasz, J; Ktos, K; Polubiec, A; Stepka, K; Strazynska, R; Weuta, H, 1988)
"Ciprofloxacin has been one of the most widely used fluoroquinolones and has a well-known safety profile, as well as excellent activity against most of the common uropathogens."	6.43	The treatment of urinary tract infections and use of ciprofloxacin extended release. ( Carson, CC; Hickerson, AD, 2006)
"Ciprofloxacin is a widely used fluoroquinolone with high bactericidal activity against uropathogens and well established clinical efficacy in the treatment of UTIs."	6.42	Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. ( Blondeau, JM, 2004)
" The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance."	6.42	Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. ( Elkharrat, D; Naber, KG; Palou, J; Talan, DA, 2004)
"Hospitalized adults with pyuria, bacteriuria, and signs and symptoms of complicated urinary tract infection (cUTI) were randomized to 5 days of IV sulopenem followed by oral sulopenem etzadroxil/probenecid or 5 days of IV ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate, depending on uropathogen susceptibility."	5.69	Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. ( Akinapelli, K; Aronin, SI; Breen, J; Das, AF; Dunne, MW; Puttagunta, S; Zelasky, MT, 2023)
"We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women."	5.51	Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. ( Bonten, MJM; Branger, J; Geerlings, SE; Hassing, RJ; Hoepelman, AIM; Ketels, T; Koldewijn, EL; Koster, A; Kuiper, S; Ten Doesschate, T; van den Bijllaardt, W; van der Bij, AK; van Mens, SP; van Nieuwkoop, C; van Werkhoven, CH, 2022)
"The cephalosporin class has been associated with an increased risk of bleeding among elderly patients receiving warfarin."	5.43	Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections. ( Balmat, RP; Saum, LM, 2016)
"His rhythm revealed torsade de pointes, which required defibrillation."	5.38	Ciprofloxacin-induced torsade de pointes. ( Ibrahim, M; Omar, B, 2012)
"We studied the tolerance and pharmacokinetic parameters of ciprofloxacin in (2 mg/kg, i."	5.30	Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI). ( Barberi, I; De Sarro, A; Masaracchio, A; Naccari, F; Salpietro, DC, 1998)
" This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract infection and/or pyelonephritis."	5.27	Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections. ( Bentley, C; Dalhoff, A; Fischer, C; Lückermann, M; Naber, K; Nowicki, M; Vente, A; Wagenlehner, F; Wohlert, S, 2018)
"coli urinary tract infections as Alternative Stepdown Treatment) is a randomized, double-blind, double-dummy, non-inferiority trial in which 240 patients will be randomly allocated to a stepdown treatment with FT or ciprofloxacin (standard of care) for FUTI, caused by Escherichia coli with in vitro susceptibility to both antibiotics."	5.27	Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST). ( Bonten, MJM; Geerlings, SE; Hoepelman, AIM; Ten Doesschate, T; van Mens, SP; van Nieuwkoop, C, 2018)
"Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h."	5.27	In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ( Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988)
" Adverse reactions were spontaneously reported by four of the 28 patients (14%) and by 11 (39%) after detailed inquiry."	5.27	Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. ( Boerema, J; Boll, B; Branolte, J; Muytjens, H, 1985)
"Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture were included in a randomized, double-blind clinical trial."	5.22	A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. ( Allegrini, A; García-Larrosa, A; Pavone, D; Salvatorelli, N, 2016)
"Furagin (a nitrofurantoin analogue) has the same efficacy in treating acute cystitis as ciprofloxacin, however the duration of therapy is longer."	5.13	Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. ( Borkowski, A; Dybowski, B; Gromadzka-Ostrowska, J; Jabłońska, O; Radziszewski, P, 2008)
"A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)."	5.13	A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008)
"To determine the efficacy of prophylactic ciprofloxacin in preventing urinary tract infections caused by urodynamic study (UDS)."	5.12	Effectiveness of ciprofloxacin prophylaxis in preventing bacteriuria caused by urodynamic study: a blind, randomized study of 192 patients. ( Kale, M; Kartal, ED; Kiremitci, A; Meric, H; Usluer, G; Yenilmez, A, 2006)
"To evaluate whether 1 week of ciprofloxacin before percutaneous nephrolithotomy (PCNL) in patients with stones of > or = 20 mm or pelvicalyceal dilatation, reduces urosepsis, as we previously reported that such patients have four times the risk of urosepsis after PCNL."	5.12	One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. ( Mariappan, P; Moussa, SA; Smith, G; Tolley, DA, 2006)
"The objective of this multicenter, randomized, controlled, parallel group trial was to evaluate the efficacy of levofloxacin 250 mg oral, once daily (LVFX), placebo one tablet oral once daily (Placebo [P] group) and ciprofloxacin (CPFX) 500 mg oral, twice daily (single blind), prophylaxis in preventing bacteriuria (> or = 10(3) CFU/ml) in post-surgical catheterized patients."	5.12	A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. ( Drago, L; Esposito, S; Leone, S; Marchetti, F; Marvaso, A; Noviello, S, 2006)
"This report focuses on the role of Pseudomonas aeruginosa in complicated urinary tract infections in a prospective, open-label, multicenter study designed to evaluate the safety and efficacy of extended-release ciprofloxacin (ciprofloxacin XR) 1000 mg once daily for 7-14 days for the treatment of complicated urinary tract infections."	5.12	Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa. ( Benson, A; Haverstock, D; Herrington, J; Perroncel, R; Pertel, P; Saltzstein, D; Wachs, B, 2007)
"We assessed the efficacy and safety of 1,000 mg extended release ciprofloxacin orally once daily vs conventional 500 mg ciprofloxacin orally twice daily, each for 7 to 14 days, in patients with a complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis (AUP)."	5.11	Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. ( Church, DA; Klimberg, IW; Kowalsky, SF; Nicolle, LE; Song, J; Talan, DA, 2004)
" In well designed clinical trials, good clinical and bacteriological efficacy (similar to that of ciprofloxacin, amoxicillin/clavulanic acid or pefloxacin) was seen with prulifloxacin 600 mg once daily for 10 days in patients with acute exacerbations of chronic bronchitis or complicated lower urinary tract infections (UTIs), and with single-dose prulifloxacin 600 mg in acute, uncomplicated lower UTIs."	5.11	Prulifloxacin. ( Keam, SJ; Perry, CM, 2004)
"The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs)."	5.11	Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. ( Carmignani, G; De Rose, AF; Dionisio, P; Olivieri, L; Rosignoli, MT; Salvatori, E, 2005)
"Pre-menopausal women presenting with acute uncomplicated cystitis were randomized to treatment with 3 days of ciprofloxacin, 7 days of nitrofurantoin, or a single dose of fosfomycin."	5.11	Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. ( Gupta, K; Hooton, TM; Stamm, WE, 2005)
"This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis."	5.10	A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. ( Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY, 2002)
"Ciprofloxacin is considered to be the standard treatment for patients with complicated urinary tract infections (UTI)."	5.09	Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group. ( Krcmery, S; Naber, KG, 1999)
"The study was undertaken to compare the safety and efficacy of twice-daily ciprofloxacin for 3 days with standard 7 day therapy with either co-trimoxazole or nitrofurantoin in the treatment of women with acute, uncomplicated urinary tract infections (UTI)."	5.09	A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. ( Briefer, C; Echols, RM; Iravani, A; Klimberg, I; Kowalsky, SF; Munera, C, 1999)
" They were compared with 23 acute pyelonephritis patients given ciprofloxacin in a dose 1 g/day."	5.09	[Tavanik effectiveness and safety in the treatment of urinary tract infection complications]. ( Loran, OB; Pushkar', DIu; Rasner, PI, 2001)
"To compare the efficacy and safety of ciprofloxacin (CIP) oral suspension to trimethoprim/sulfamethoxazole (TMP/SMX) oral suspension among older women with acute urinary tract infections (UTIs)."	5.09	Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. ( Gomolin, IH; Haverstock, DC; Heyd, A; Reuning-Scherer, J; Siami, PF, 2001)
" It is concluded that ciprofloxacin may be more effective to preventing immediate urinary tract infections after TURP than a combination of sulfadiazine and trimethoprim."	5.08	Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. ( Hellström, P; Kontturi, M; Leppilahti, M; Lukkarinen, O; Tammela, T, 1996)
"A total of 686 adult patients with complicated urinary tract infections were enrolled in a double-blind, randomised, multicentre study to compare sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily) with ciprofloxacin (500 mg orally twice daily) for 10 to 14 days."	5.08	Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. ( di Silverio, F; Geddes, A; Guibert, J; Naber, KG, 1996)
"The efficacy and safety of lomefloxacin 400 mg daily in the treatment of complicated urinary tract infections were confirmed in a randomized multicenter study that enrolled 294 patients from 16 centers in Italy."	5.08	Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. ( Bartoletti, R; Pisani, E; Rizzo, M; Trinchieri, A, 1996)
"We evaluated and compared the efficacy of post-intercourse and daily oral ciprofloxacin prophylaxis against recurrent lower urinary tract infections in 135 sexually active premenopausal women."	5.08	Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. ( Asbach, HW; Gerharz, E; Melekos, MD; Naber, KG; Weingaertner, K; Zarakovitis, IE, 1997)
"An open randomized prospective study was carried out on 72 patients with urinary retention undergoing TURP, to compare of 500 mg of ciprofloxacin (CF) orally twice daily and 1 g of ceftazidime (CT) intravenously twice daily."	5.08	Antibiotic prophylaxis in patients with urinary retention undergoing transurethral prostatectomy. ( Hellström, P; Kontturi, M; Leppilahti, M; Lukkarinen, O; Tammela, T, 1997)
"To evaluate the efficacy of low-dose long-term treatment with ciprofloxacin in the prevention of recurrent urinary tract infections in patients with spinal cord lesions and neurogenic bladder dysfunction, a prospective, randomized, cross-over, placebo-controlled study was performed."	5.07	Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. ( Biering-Sørensen, F; Bruun, B; Høiby, N; Nordenbo, A; Rahm, V; Ravnborg, M, 1994)
"A total of 125 ambulatory women (85 premenopausal and 40 postmenopausal) who experienced 174 acute urinary tract infections with mainly gram-negative bacteria (99%) was randomized to receive a single dose, 2-tablet treatment with either ofloxacin (400 mg."	5.07	Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. ( Pfau, A; Sacks, TG, 1993)
"In this large, multicenter, double-blind clinical trial, 404 women with acute, uncomplicated urinary tract infections (UTI) were randomized to receive temafloxacin 400 mg once daily for 3 days, or ciprofloxacin 250 mg twice daily for 7 days."	5.07	Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. ( Philip, E; Stein, GE, 1992)
"The efficacy and safety of two fluoroquinolone antimicrobial agents, lomefloxacin and ciprofloxacin, were compared in a randomized, investigator-blinded, multiple-dose study that enrolled 150 adult outpatients with complicated or recurrent urinary tract infections."	5.07	A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. ( Cox, CE, 1992)
"We conducted a randomized, double-blind trial to compare low-dose trimethoprim-sulfamethoxazole with ciprofloxacin for the prevention of urinary tract infections in renal transplant recipients."	5.07	Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. ( Auchincloss, H; Cosimi, AB; Delmonico, FL; Delvecchio, A; Doran, M; Hibberd, PL; Rubin, RH; Tolkoff-Rubin, NE, 1992)
"In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration."	5.07	[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991)
"Intravenous ciprofloxacin and ceftazidime were compared for efficacy in the treatment of nosocomial pneumonia and urinary tract infection (UTI)."	5.07	Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. ( Billeter, M; Dempsey, RJ; Hatton, J; Rapp, RP; Tibbs, PA; Young, AB, 1991)
"In a double-blind randomized trial, we evaluated the efficacy and safety of three oral dosage regimens of fleroxacin, a new fluoroquinolone, once daily in 62 patients for the treatment of complicated urinary tract infections."	5.06	Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections. ( Hoepelman, AI; Verhoef, J; Wolfhagen, MJ, 1990)
"Urinary tract infections in 32 patients were treated with 250 mg of ciprofloxacin twice daily for seven to eight days."	5.06	Treatment of urinary tract infections with ciprofloxacin. ( Bonamini, A; Curotto, A; Giberti, C; Martorana, G; Oneto, F; Pizzorno, R; Soro, O, 1988)
"A double-blind, randomised, placebo-controlled study was carried out to determine the incidence and significance of bacteriuria in 110 patients undergoing transurethral resection of the prostate (TURP) and to assess the effect of a single pre-operative dose of Ciprofloxacin, a 4-quinolone antibiotic."	5.06	Single dose, oral antibiotic cover for transurethral prostatectomy. ( Burdon, DW; Farrar, DJ; Johnson, M; Keighley, MR; Shearman, CP; Silverman, SH; Young, CH, 1988)
"Multi-resistant nosocomial urinary tract infections occurring in thirty patients with neurogenic bladder dysfunction were treated with ciprofloxacin 100 mg twice daily Early bacteriological eradication was obtained in 48."	5.06	Treatment of multi-resistant urinary tract infections in patients with multiple sclerosis. ( Baert, L; van Poppel, H, 1987)
"Seventy-five hospital inpatients with bacteriologically confirmed urinary tract infections were allocated to treatment with ciprofloxacin 100 mg, ciprofloxacin 250 mg or co-trimoxazole 960 mg, all given orally twice a day for five days."	5.06	Ciprofloxacin and co-trimoxazole in urinary tract infection. ( Grüneberg, RN; Williams, AH, 1986)
"Ofloxacin was administered to 18 patients and ciprofloxacin to 17 patients suffering from acute or chronic complicated urinary tract infections."	5.06	Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. ( Kromann-Andersen, B; Larsen, V; Pers, C; Rasmussen, F; Sommer, P, 1986)
"Two single-dose regimens of ciprofloxacin, 100 and 250 mg, were compared in the treatment of uncomplicated urinary tract infections in women."	5.06	Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. ( Flepp, M; Garlando, F; Lüthy, R; Meier, B; Rietiker, S; Täuber, MG, 1987)
"In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections."	5.06	Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. ( Alpert, ML; Citron, DM; Ginsberg, BP; Goldstein, EJ; Greenway, FL; Kahn, RM, 1987)
"Ciprofloxacin treatment of urinary tract infections in 23 patients (16 with and seven without urorenal abnormalities) was compared with beta-lactam antibiotic therapy given orally to 10 comparable patients."	5.06	Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. ( Daikos, GL; Jackson, GG; Kathpalia, SB; Lolans, VT; Sharifi, R, 1987)
"The effectiveness and safety of ciprofloxacin, a new quinolone antibiotic, were prospectively evaluated in the treatment of patients with complicated urinary tract infections caused by gram-negative organisms resistant to trimethoprim/sulfamethoxazole."	5.06	Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. ( Bittner, MJ; Cuevas, TA; Mellencamp, MA; Preheim, LC; Roccaforte, JS, 1987)
"2 years), with urinary tract infections caused by Pseudomonas species or other organisms resistant to trimethoprim-sulfamethoxazole were treated with 500 mg of orally administered ciprofloxacin every 12 hours."	5.06	Oral ciprofloxacin in resistant urinary tract infections. ( Andriole, VT; Berenson, CS; Greco, TP; Mangi, RJ; Ryan, JL; Sims, M; Thornton, GF, 1987)
" For treatment of uncomplicated VRE urinary tract infections, ciprofloxacin or nitrofurantoin can be used."	4.98	[Treatment of vancomycin-resistant enterococcal infections]. ( Holzknecht, BJ; Justesen, US; Lund, LC, 2018)
" The duration of treatment for uncomplicated pyelonephritis can be safely shortened to 7 days when using ciprofloxacin."	4.89	[Infectious diseases]. ( Malinverni, R; Pittet, R, 2013)
"Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)."	4.85	Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. ( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009)
" For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)."	4.84	[Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007)
" The vast majority of Enterobacteriaceae, including ESBL producers, remain susceptible to carbapenems, and these agents are considered preferred empiric therapy for serious Enterobacteriaceae infections."	4.83	Resistance in gram-negative bacteria: enterobacteriaceae. ( Paterson, DL, 2006)
"Pharmacodynamic profiling of oral ciprofloxacin dosing for urinary tract infections caused by ceftriaxone-resistant Escherichia coli isolates with ciprofloxacin MIC ≥ 0."	4.31	Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model. ( Abbott, IJ; Cottingham, H; Macesic, N; Meletiadis, J; Peleg, AY; Roberts, JA; van Gorp, E; Wallis, SC, 2023)
"Our study indicated the inhibitory effect of ciprofloxacin and ceftriaxone on the level of hemolysis, suggesting that the sub-inhibitory concentrations of these antibiotics may affect the outcome of infections."	4.12	Characterization of Escherichia coli isolated from urinary tract infection and association between virulence expression and antimicrobial susceptibility. ( Aghaei, A; Ahmadi, E; Ahmadi, S; Derakhshan, S; Nasseri, S, 2022)
"The old antimicrobial nitroxoline is currently repurposed for oral treatment of uncomplicated urinary tract infections (UTIs)."	4.12	In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract. ( Becerra-Aparicio, F; Fuchs, F; Higgins, PG; Seifert, H; Xanthopoulou, K, 2022)
"These cases illustrate that cefoxitin is an interesting alternative to carbapenems, even in severe infections such as endocarditis."	4.12	Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis. ( Courtois, R; Danneels, P; Dubée, V; Eveillard, M; Kempf, M; Mahieu, R; Quinqueneau, C; Rihet, C; Vannier, C, 2022)
"Women with any history of kidney stones may have bacteriuria resistant to nitrofurantoin, suggesting that providers might consider alternative antibiotic therapies in this scenario."	4.12	Can Urinalysis and Past Medical History of Kidney Stones Predict Urine Antibiotic Resistance? ( Craver, EC; Heckman, MG; Mohseni, M; Sheele, JM, 2022)
"Fluoroquinolones, such as ciprofloxacin and levofloxacin, are broad-spectrum antibacterial agents that have historically been widely used for urinary tract infections, pneumonia, and intra-abdominal infections but are associated with several serious adverse reactions, including tendinopathy and tendon rupture, peripheral neuropathy, and aortic aneurysm."	4.12	A preventable, life-altering case of fluoroquinolone-associated tendonitis. ( Holmes, M; Wildermuth, A, 2022)
"ciprofloxacin was primarily indicated for urinary tract infections."	4.02	Hospital-based ciprofloxacin use evaluation in Eastern Ethiopia: a retrospective assessment of clinical practice. ( Abebe, FA; Embiale, YB; Hailegiyorgis, TT; Shiferaw, MS; Tekalign, TG, 2021)
"A search was made on the World Health Organization global adverse drug reaction database (August 15, 2018) using "ciprofloxacin" as the drug substance and "hypoglycemia" as the reaction term."	3.91	Ciprofloxacin and risk of hypolycemia in non-diabetic patients. ( Bahran, F; Berhe, A; Hagos, G; Russom, M, 2019)
"Considering the global concern of ciprofloxacin resistance, the aim of this study was to evaluate the characteristics of ciprofloxacin-resistant (CIP-R) Escherichia coli isolated from patients with community-acquired urinary tract infections (UTIs) in Brasília, Brazil."	3.85	Ciprofloxacin resistance in uropathogenic Escherichia coli isolates causing community-acquired urinary infections in Brasília, Brazil. ( de Campos, TA; de Melo, ABF; de Oliveira Martins Júnior, P; de Paulo Martins, V; Gonçalves, LF; Moreira da Silva, RCR; Pitondo-Silva, A, 2017)
"urinary tract infections."	3.85	In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. ( Linasmita, P; Tantisiriwat, W, 2017)
"Antimicrobial resistance to ciprofloxacin is rising worldwide, especially in bacteria causing urinary tract infections (UTIs)."	3.85	Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. ( de Visser, H; Goessens, WH; Hofman, A; Kiefte-de Jong, JC; Mulder, M; Stricker, BH; Verbon, A, 2017)
" Treatment in indoor locations, presence of urinary catheters and pregnancy along with recent exposure to antibiotics especially fluoroquinolones, third generation cephalosporins and piperacillin-tazobactam were identified as independent risk factors."	3.83	Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India. ( Anupurba, S; Banerjee, T, 2016)
"The antibiotic nitrofurantoin is commonly used to treat uncomplicated urinary tract infections."	3.81	Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. ( Gandhi, S; Garg, AX; Jain, AK; Liu, AR; McArthur, E; Moist, L; Singh, N; Sood, MM, 2015)
"Ciprofloxacin is commonly used in clinical practice for the treatment of recurrent urinary tract infections caused by Escherichia coli."	3.81	Pentacyclic triterpenes combined with ciprofloxacin help to eradicate the biofilm formed in vitro by Escherichia coli. ( Kicia, M; Tichaczek-Goska, D; Wojnicz, D, 2015)
"0001) reduction in ciprofloxacin prescribing for cystitis, while the use of mecillinam increased (p = 0."	3.80	A simple intervention to reduce inappropriate ciprofloxacin prescribing in the emergency department. ( Berild, D; Fagan, M; Lindbæk, M; Reiso, H, 2014)
"Discordant empirical therapy, mostly with ciprofloxacin, leads to worse early clinical response and longer hospital stay than concordant therapy in community-acquired bacteremic acute pyelonephritis, although it does not affect on overall mortality or clinical cure rate."	3.77	Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. ( Chung, DR; Kim, Y; Lee, SS, 2011)
"The aim of this study was to obtain data on susceptibility patterns of pathogens responsible for both community and hospital urinary tract infections (UTIs); and analyzed risk factors for infection caused by ciprofloxacin-resistant Escherichia coli and extended-spectrum β-lactamase (ESBL)-producing strains in Rwanda."	3.77	Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines. ( Bayingana, C; Claeys, GW; Masaisa, F; Muhirwa, G; Musemakweri, A; Mutesa, L; Muvunyi, CM, 2011)
"Resistance to ciprofloxacin in Escherichia coli from urinary tract infections (UTI) in Denmark is increasing parallel to increased use of fluoroquinolones both in Denmark and in other European countries."	3.77	Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country. ( Christiansen, N; Frimodt-Møller, N; Hansen, LH; Jakobsen, L; Nielsen, L; Stegger, M, 2011)
"The aims of this study were to investigate the prevalence of qnrA, qnrB, and qnrS determinants and their molecular characteristics in ciprofloxacin-resistant isolates of Escherichia coli and Klebsiella pneumoniae from urinary tract infections (UTI) in Korea."	3.74	High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. ( Chang, CL; Jung, HJ; Kim, HR; Lee, JN; Lee, JY; Shin, JH, 2008)
"We present a case of Achilles tendinitis in a 77-year-old patient with renal dysfunction and a urinary tract infection (UTI) treated with ciprofloxacin 250 mg PO QD."	3.74	An elderly patient with fluoroquinolone-associated achilles tendinitis. ( Cinti, SK; Damuth, E; Heidelbaugh, J; Malani, PN, 2008)
"Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E."	3.74	In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007)
"Comparative susceptibility of microflora isolates from patients with complicated urinary tract infections to cefepime, other cephalosporins, amikacin, ciprofloxacin and ofloxacin was studied."	3.72	[Cefepime (maxipime) in the treatment of severe urinary tract infection]. ( Derevianko, II, 2003)
"The prevalence of hemolysin, type 1 fimbriae, P fimbriae, cytotoxic necrotizing factor-1 (CNF-1), aerobactin, and autotransporter toxin (sat) was analyzed by polymerase chain reaction and phenotypic assays of 42 epidemiologically unrelated Escherichia coli strains causing acute pyelonephritis in women (21 nalidixic acid-susceptible and 21 nalidixic acid-resistant strains) and 58 E."	3.71	Are quinolone-resistant uropathogenic Escherichia coli less virulent? ( Barranco, M; Horcajada, JP; Mensa, J; Moreno, A; Ruiz, J; Simon, K; Velasco, M; Vila, J, 2002)
"We studied gastrointestinal (GI) colonization by Candida albicans in patients receiving oral norfloxacin, ciprofloxacin or ofloxacin as monotherapy for urinary tract infections."	3.71	The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. ( Cranidis, A; Kontoyiannis, DP; Maraki, S; Mavromanolakis, E; Samonis, G; Tselentis, Y, 2001)
"A simulation study was performed to evaluate and compare the standard dosage regimen of 250 mg/12 h versus 500 mg/24 h of ciprofloxacin for the treatment of urinary tract infections (UTIs)."	3.71	Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. ( Sánchez Navarro, A; Sánchez Navarro, MD; Sayalero Marinero, ML, 2002)
"A study was performed in 25 men with spinal cord injuries undergoing intermittent catheterization whose urine had > or = 10(5) bacterial colonies/ml to determine efficacy of ciprofloxacin in eradicating susceptible organisms from urine, urethra, and perineum."	3.70	Effect of oral ciprofloxacin on bacterial flora of perineum, urethra, and lower urinary tract in men with spinal cord injury. ( Brookings, ES; Canupp, KC; DeVivo, MJ; Waites, KB, 1999)
"To detect if isolates susceptible to quinolones already carry mutations in the gyrA and parC genes, we selected 12 ciprofloxacin-susceptible Escherichia coli strains collected from patients with urinary tract infections in Latin America in 1998, as part of ongoing SENTRY Antimicrobial Surveillance Program."	3.70	Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. ( Gales, AC; Gordon, KA; Jones, RN; Pfaller, MA; Wilke, WW, 2000)
"The effects of mecillinam, trimethoprim and ciprofloxacin, antibiotics used in the treatment of urinary tract infections, on the aquatic environment were assessed."	3.70	Environmental risk assessment of antibiotics: comparison of mecillinam, trimethoprim and ciprofloxacin. ( Andersen, HR; Halling-Sørensen, B; Ingerslev, F; Lützhøft, HC, 2000)
"Ciprofloxacin may be considered as first-line treatment for a number of infections in which gram-negative pathogens are proven or strongly suspected, including complicated urinary tract infections, bacterial prostatitis, bacterial diarrhea, selected bone and joint infections, malignant otitis externa, bronchopulmonary infections in patients with cystic fibrosis and selected pneumonia cases."	3.69	Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society. ( Louie, TJ, 1994)
"As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study."	3.68	Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993)
"In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week."	3.67	Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. ( Chysky, V; Dammekens, H; Van Poppel, H; Wegge, M, 1986)
"The efficacy and safety of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections was evaluated in 72 patients suffering from upper urinary tract infection (19 patients), deep soft tissue infection (16), chronic osteomyelitis (12), abscess (7), chronic otitis media (6), otitis externa (3) and bronchopneumonia (9)."	3.67	Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. ( Daikos, GK; Daphnis, E; Dendrinos, C; Galanakis, N; Giamarellou, H; Stefanou, J, 1986)
" Among quinolones, the most active agents are ciprofloxacin and ofloxacin (MIC modes: 4 and 2 mg/l), so these antimicrobials could be used for the treatment of urinary tract infections caused by Corynebacterium group D2."	3.67	[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity]. ( Cancet, B; Clave, D; Didier, J; Henry-Ferry, S; Marty, N, 1988)
"The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections."	3.67	Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988)
"Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa."	3.67	Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986)
"Eighty-three patients with serious urinary tract infections were treated with oral ciprofloxacin."	3.67	Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections. ( Fass, RJ, 1987)
"The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)."	3.67	Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986)
" Adverse reactions of the kidneys to ciprofloxacin are rare, but sometimes severe."	2.82	Is ciprofloxacin safe in patients with solitary kidney and upper urinary tract infection? ( Bob, F; Bozdog, G; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Velciov, S, 2016)
"Urinary tract infections are among the most common nosocomial infections."	2.74	Antibiotic prophylaxis at urinary catheter removal prevents urinary tract infections: a prospective randomized trial. ( Ackermann, C; Lea, S; Moldenhauer, J; Peterli, R; Pfefferkorn, U; von Flüe, M, 2009)
"The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial."	2.71	Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004)
"The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)."	2.71	Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004)
"Ciprofloxacin was used in doses of 500 or 1000 mg orally once a day depending on the severity of the disease singns for 2-3 weeks as etiotropic therapy and only in 2 cases with severe pyelonephritis it was used intravenously drop-wise and orally simultaneously."	2.71	[Therapy of urinary tract infections in patients with diabetes mellitus]. ( Babarina, MB; Orlov, VA; Sokolova, VI, 2005)
"Ciprofloxacin is an useful antimicrobial for the treatment of lower urinary tract infection in women."	2.69	[Efficacy and tolerance of a five day course of ciprofloxacin in the treatment of urinary tract infection in women. Multicenter study]. ( Castrillón, M; Cumsille, F; Flaskamp, R; Haristoy, J; Martínez, J; Montaño, R; Prado, V; Sepúlveda, S; Zemelman, R, 1998)
" A once-daily dosage of 400 mg i."	2.69	Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. ( Moneva-Koucheva, G; Naber, KG; Stass, H; Theuretzbacher, U, 1999)
"Three studies were undertaken to determine the minimum effective dosing regimen of ciprofloxacin for the treatment of acute, symptomatic, uncomplicated lower urinary tract infection."	2.68	Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. ( Gallis, HA; Heyd, A; Iravani, A; Kowalsky, SF; McCarty, J; Nolen, T; Sikes, DH; Tice, AD; Tosiello, RL; Whalen, EP, 1995)
" The patients were treated with Bay-o-9867 (ciprofloxacin) administered orally at a daily dosage of 500 mg (250 q 12 h) in 30 patients and of 1000 mg (500 q 12 h) in 10 patients, depending on the severity of infection."	2.67	[The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract]. ( Bolognesi, S; Quartieri, F; Sconosciuto, F, 1994)
"Also for lower respiratory tract infections (LTRI) the clinical and bacteriological responses were quite similar, although relatively more failures occurred in CF treated patients with LRTI caused by pneumococci."	2.67	Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. ( Andersen, BM; Bergan, T; Brubakk, O; Bruun, JN; Døskeland, B; Hellum, KB; Hopen, G; Kalager, T; Rahm, V; von der Lippe, E, 1992)
"Ciprofloxacin was well tolerated."	2.67	Value of single-dose ciprofloxacin in the treatment of acute uncomplicated urinary tract infection in women. ( Adracta, DJ; Georgiopoulos, AN; Karachalios, GN; Nasopoulou-Papadimitriou, DD, 1991)
"Ciprofloxacin was efficacious in complicated urinary tract infection compared with the current standard of parenteral aminoglycoside among catheterized patients with relatively resistant bacteria."	2.67	Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. ( Brennen, C; DeVine, J; Fang, GD; Hilf, M; Swanson, D; Wagener, M; Yu, VL; Zadecky, L, 1991)
" Amifloxacin at a dosage of 200 mg twice a day appeared as safe and effective as TMP-SMX, but amifloxacin at 400 mg twice a day tended to cause adverse events more frequently than did TMP-SMX."	2.67	Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group. ( Boyko, EJ; Iravani, A; Schelling, DJ; Silverman, MH; Wright, RA, 1990)
"Ciprofloxacin is an effective and safe treatment for uncomplicated urinary tract infection in general practice."	2.66	Ciprofloxacin versus amoxycillin/clavulanic acid in the treatment of urinary tract infections in general practice. ( Abbas, AM; Chandra, V; Dongaonkar, PP; Goel, PK; Kacker, P; Patel, NA; Shrivastava, OP; Thakkar, B; Tillotson, GS, 1989)
"Ciprofloxacin was given orally at different dose regimens: 500 mg b."	2.66	Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988)
"Ciprofloxacin has proved to be superior to cefalexin in the treatment of lower UTI."	2.66	Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study. ( Jórasz, J; Ktos, K; Polubiec, A; Stepka, K; Strazynska, R; Weuta, H, 1988)
" The drug dosage was 300 mg every 12 hours in 19 patients and 200 mg intravenously every 12 hours in nine patients."	2.66	Treatment of serious infections with intravenous ciprofloxacin. ( Neu, HC; Scully, BE, 1987)
" In general, the patients received ciprofloxacin at a dosage of 250 to 750 mg every 12 hours; the median dose was 500 mg twice daily."	2.66	Ciprofloxacin: an update on clinical experience. ( Arcieri, G; August, R; Becker, N; Griffith, E; Gruenwaldt, G; Heyd, A; O'Brien, B, 1987)
" The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance."	2.42	Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. ( Elkharrat, D; Naber, KG; Palou, J; Talan, DA, 2004)
" Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence."	2.41	The expanding role of fluoroquinolones. ( Schaeffer, AJ, 2002)
"Ciprofloxacin is an effective treatment for those infections most common in elderly patients, including infections of the urinary tract, lower respiratory tract, skin and soft-tissues, and bone and joints, and is an effective agent for prophylaxis in transurethral surgery."	2.39	Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. ( Balfour, JA; Wiseman, LR, 1994)
"Ciprofloxacin is a fluorinate quinolone with a broad spectrum of activity against gram-positive and gram-negative organisms."	2.38	[A review of clinical studies on the efficacy and tolerance of intravenous ciprofloxacin]. ( Memoli, M, 1992)
" Care in selection of patients, attention to optimal duration of therapy and adequate dosage may help to prevent emergence of resistance but combination therapy has not proven effective."	2.38	Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. ( Ball, P, 1990)
"Ciprofloxacin is a new 4-quinolone antibacterial agent with an extended antibacterial spectrum, enhanced potency and the ability to produce therapeutic serum, tissue and urine concentrations after oral administration."	2.37	Overview of clinical experience with ciprofloxacin. ( Ball, AP, 1986)
"Ciprofloxacin is a new quinolone derivative which is particularly well adapted for the treatment of bacterial urinary tract infection."	2.37	Ciprofloxacin in management of urinary tract infection. ( Rubin, RH; Tolkoff-Rubin, NE, 1988)
"We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used."	1.62	Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. ( Andriantahina, I; Angoulvant, F; Birgy, A; Bonacorsi, S; Cixous, E; Cohen, R; Craiu, I; De Pontual, L; Dommergues, MA; Dubos, F; Gajdos, V; Georget, E; Gillet, Y; Grimprel, E; Jung, C; Launay, E; Levy, C; Lignieres, G; Madhi, F; Pinquier, D; Rybak, A; Soussan-Banini, V; Vignaud, O, 2021)
"Post-URS sepsis was 7."	1.56	Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis. ( Amiel, GE; Badaan, S; Kastin, A; Kravtsov, A; Mullerad, M; Zisman, A, 2020)
"CIP displayed linear PK with dose proportional increase in Cmax and AUCinf in plasma."	1.56	Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. ( Hiremath, S; Jayaraman, R; Nanjundappa, M; Pawar, A; Puttarangappa, P; Puttaswamy, R; Reniguntla, MK; Yedle, R, 2020)
"Ciprofloxacin was also commonly prescribed in Italy (24."	1.56	Office-based approach to urinary tract infections in 50 000 patients: results from the REWIND study. ( Brunelli, R; Cai, T; Cipelli, R; Palagin, I; Pellini, E; Truzzi, JC; Van Bruwaene, S, 2020)
" The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde."	1.56	Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli. ( Almeida, VSS; Carvalho Júnior, AR; da Silveira, BC; de Araújo, TS; de Oliveira, NMT; de Souza, CD; Fernandes, ES; Ferro, TAF; Gonzaga, LF; Maria-Ferreira, D; Martins, WC; Mendes, SJF; Monteiro-Neto, V; Pessoa, JFV; Pontes, JP; Santos, DM; Sousa, NCF, 2020)
"Ciprofloxacin resistance was detected in 33% and ESBL positivity in 22% of the isolated E."	1.56	The Role of Ciprofloxacin Resistance and Extended-spectrum beta-lactamase (ESBL) Positivity in Infective Complications Following Prostate Biopsy. ( Gurbuz, Y; Korkmaz, N; Kul, G; Sandikci, F; Sencan, I; Tutuncu, EE, 2020)
"In a recent multicenter population pharmacokinetic study of ciprofloxacin administered to children suffering from complicated urinary tract infection (cUTI), the apparent volume of distribution (V) and total plasma clearance (CL) were decreased by 83."	1.51	Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection. ( Balbas-Martinez, V; Edginton, AN; Meesters, K; Michelet, R; Trocóniz, IF; Vermeulen, A, 2019)
"Malacoplakia is a rare chronic inflammatory disease that most commonly involves the genitourinary tract with a wide spectrum of clinical presentation."	1.48	Bilateral hydroureteronephrosis with renal failure caused by malacoplakia. ( Audino, P; Cavallone, B; Di Stasio, A; Serao, A; Tiranti, D; Vota, P, 2018)
"Negative myoclonus is characterized by a brief sudden loss of muscle activity, and can be caused by a variety of acquired factors and epilepsy syndromes."	1.46	Negative Myoclonus Induced by Ciprofloxacin. ( De Kleermaeker, FGCM; Te Riele, MGE; van Samkar, A; Verrips, A, 2017)
"The cephalosporin class has been associated with an increased risk of bleeding among elderly patients receiving warfarin."	1.43	Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections. ( Balmat, RP; Saum, LM, 2016)
"Ciprofloxacin resistance was found in 90."	1.43	The prevalence of urinary tract infection, or urosepsis following transrectal ultrasound-guided prostate biopsy in a subset of the Saudi population and patterns of susceptibility to flouroquinolones. ( Albqami, NM; AlKhateeb, SS; Alrabeeah, KA; AlShammari, NA; AlZughaibi, MA; Ghazwani, YG, 2016)
"Empirical and prolonged antimicrobial treatment of urinary tract infections caused by Escherichia coli is associated with the emergence of bacterial resistance, and not all countries have strict policies against the indiscriminate use of drugs in order to prevent resistance."	1.43	Antibiotic Resistance of Bacteria Involved in Urinary Infections in Brazil: A Cross-Sectional and Retrospective Study. ( Araújo, MC; De Resende, EA; Lazo-Chica, JE; Miguel, CB; Nogueira, AP; Oliveira, CJ; Paulino, Tde P; Rodrigues, WF; Soares, Sde C; Ueira-Vieira, C, 2016)
"When bacteremia is significant, it occurs mostly in patients with hematologic malignancies and is predominantly catheter-related."	1.42	Staphylococcus saprophyticus bacteremia after ESWL in an immunocompetent woman. ( Boel, A; De Beenhouwer, H; Hofmans, M; Van Vaerenbergh, K, 2015)
"Emphysematous cystitis is a very rare complicated urinary tract infection characterized by air in the bladder wall."	1.42	Emphysematous cystitis presenting as severe confusion and abdominal pain: two case reports. ( De Coninck, V; Michielsen, D, 2015)
"Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0."	1.42	Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. ( Gupta, K; Lerner, L; Marino, K; Orlando, R; Parlee, A; Strymish, J, 2015)
"Ciprofloxacin resistance has risen fairly quickly in the last four years from 1% to 8%."	1.42	Local audit: How tightly should we police antibiotic prescribing for urinary tract infection and how should we modify national policy? ( Brair, A; Gray, J; Toozs-Hobson, P, 2015)
"Amikacin was the most effective antibiotic against gram-negative isolates while Ciprofloxacin was the most effective antibiotic against Staphylococcus saprophyticus."	1.42	Urinary Tract Infection among Renal Transplant Recipients in Yemen. ( Al-Moyed, KA; Al-Robasi, AB; Al-Shamahy, HA; Alyousefi, NA; Gondos, AS, 2015)
"It is extremely rare that the urinary bladder stones cause vesicorectal fistulas."	1.40	Is vesicolithotomy with bladder wash the answer for rectovesical fistula secondary to neglected vesical stone? Complicated presentation but simple management. ( Elnaim, AK; Mohamed, MM, 2014)
"Bacteriuria was present in 9% of the subjects."	1.40	Occurrence of urinary tract infection in adolescent and adult women of shanty town in Dhaka City, Bangladesh. ( Ahmed, MF; Begum, A; Rahman, SR, 2014)
"Ciprofloxacin is a commonly used antibiotic."	1.40	Ciprofloxacin-induced crystal nephropathy. ( Ben Hmida, M; Ben Mahmoud, L; Boudawara, T; Hachicha, J; Jarraya, F; Kammoun, K; Kharrat, M; Makni, S; Zeghal, K, 2014)
"The ciprofloxacin MIC range was 0."	1.40	Detection of plasmid-mediated qnr genes among the quinolone-resistant Escherichia coli isolates in Iran. ( Firoozeh, F; Soleimani-Asl, Y; Zibaei, M, 2014)
" When the most potent representative, an indolinylphenyl mannoside, was administered in a mouse model at the low dosage of 1 mg/kg (corresponding to approximately 25 μg/mouse), the minimal therapeutic concentration to prevent UTI was maintained for more than 8 h."	1.38	Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. ( Abgottspon, D; Ernst, B; Haug, M; Jiang, X; Kleeb, S; Rabbani, S; Scharenberg, M; Schwardt, O; Wittwer, M, 2012)
"His rhythm revealed torsade de pointes, which required defibrillation."	1.38	Ciprofloxacin-induced torsade de pointes. ( Ibrahim, M; Omar, B, 2012)
"For ciprofloxacin the ORs were 2."	1.38	Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. ( Bennett, K; Cormican, M; Hanahoe, B; Murphy, AW; Tansey, S; Vellinga, A, 2012)
"Traditional first-line treatment of chronic bacterial prostatitis (CBP) is administration of empirical antibiotics."	1.37	Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model. ( Cho, YH; Ha, US; Han, CH; Kim, HW; Kim, SH; Lee, CB; Lee, HR; Lee, SJ; Sohn, DW, 2011)
"Ciprofloxacin was used in a large proportion of the patients in cases when another antibiotic should have been the first choice according to Norwegian national guidelines."	1.36	[Use of fluoroquinolones in nursing homes]. ( Fagan, M; Skotheim, SB, 2010)
"Bacterial prostatitis is documented at a very low prevalence (7-13% of prostatitis overall considered) due to either reduced utilization of viral and bacteriological tests (Meares test, urethral swab, bacterial and viral PCR) or to the possibility that individual patients show a scarce expression of bacterial disease in biological fluids, because of intraglandular biofilm presence, with subsequent spreading of the sole plankton microrganisms."	1.35	[Chronic prostatitis and biofilm]. ( Bartoletti, R; Cai, T, 2009)
"Here, we present a case of Escherichia coli meningitis after TBP despite quinolone prophylaxis."	1.35	Acute bacterial meningitis after transrectal needle biopsy of the prostate: a case report. ( Arslan, H; Ekinci, MN; Erdogan, A; Erdogan, H; Hoscan, MB, 2008)
"A total of 360 patients with renal and ureteral calculi who had sterile urine before extracorporeal shock wave lithotripsy (ESWL) and did not have any increased risk of infection received Tab."	1.33	Necessity of antibiotics prophylaxis during extracorporeal shock wave lithotripsy. ( Ahasan, DN; Choudhury, GM; Islam, MA; Shameem, IA; Wahab, MA, 2005)
"The ciprofloxacin therapy was discontinued."	1.33	Prolonged electroconvulsive therapy seizure in a patient taking ciprofloxacin. ( Aydemir, C; Cebeci, S; Goka, E; Kisa, C; Yildirim, SG, 2005)
"Ciprofloxacin therapy was initiated and renal function was restored within 2 days."	1.33	Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia. ( Burghardt, KM; Feber, J; Filler, G; Halton, J; Leonard, M, 2006)
"Ciprofloxacin was evaluated along with other commonly-used antibiotics against a total of 480 clinical isolates obtained from urine samples."	1.33	Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in the Gaza Strip. ( Astal, ZE, 2005)
" pneumoniae, MPC results were below susceptible breakpoints and within clinically achievable and sustainable drug concentrations for >24 hours of the dosing interval against."	1.33	Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. ( Blondeau, JM; Hansen, GT, 2005)
"An in vitro kinetic model was used to measure MPC with static antibiotic concentrations and to test different dosing profiles to study pharmacokinetics/pharmacodynamics indices important to prevent the growth of resistant mutants."	1.33	Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. ( Cars, O; Hughes, D; Komp Lindgren, P; Marcusson, LL; Olofsson, SK, 2006)
" Urine samples were taken every 2 h during the whole dosing interval of the particular antibiotic."	1.33	Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model. ( Bedenic, B; Bubonja, M; Budimir, A; Topic, M, 2006)
"Ciprofloxacin uptake was determined spectrophotometrically using the quinolone accumulation assay."	1.33	Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. ( Chenia, HY; Pillay, B; Pillay, D, 2006)
"Treatment with ciprofloxacin was given."	1.32	[Arizonae subspecies Salmonella enterica urinary infection with confusional syndrome]. ( Becq-Giraudon, B; Grignon, B; Landron, C; Le Moal, G; Roblot, F, 2003)
" Population pharmacokinetic analyses were performed with NONMEN software."	1.32	Population pharmacokinetics of ciprofloxacin in pediatric patients. ( Gastonguay, MR; Rajagopalan, P, 2003)
"Ciprofloxacin can induce interstitial pneumonitis with acute respiratory failure."	1.32	Ciprofloxacin-induced acute interstitial pneumonitis. ( Bubendorf, L; Leuppi, JD; Oberholzer, M; Steiger, D; Tamm, M, 2004)
"Skin biopsy confirmed toxic epidermal necrolysis."	1.32	Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: a case report. ( Jones, H; Mandal, B; Singh, S; Steward, M, 2004)
"A case of severe pseudomembranous colitis developing in an 8-year-old child who had received oral ciprofloxacin therapy as part of an investigational protocol is presented."	1.32	Severe ciprofloxacin-associated pseudomembranous colitis in an eight-year-old child. ( Angel, CA; Green, J; Patel, J; Swischuk, L, 2004)
"Ciprofloxacin was the only agent studied that demonstrated a consistent stepwise increase in resistance from 1995 (0."	1.31	Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. ( Jones, ME; Karlowsky, JA; Kelly, LJ; Sahm, DF; Thornsberry, C, 2002)
" Plasma concentration curves were simulated from literature values of the pharmacokinetic parameters of the drug and the age and weight of the patients."	1.31	Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. ( Coloma Milano, C; Sánchez Navarro, MD; Sánchez-Navarro, A; Sayalero Marinero, ML; Zarzuelo Castañeda, A, 2002)
"Pemphigus vulgaris is an autoimmune blistering disorder in which both genetic and environmental factors, mainly drugs, are thought to play a part in its aetiopathogenesis."	1.31	A case of pemphigus vulgaris possibly triggered by quinolones. ( Anadolu, RY; Birol, A; Bostanci, S; Boyvatt, A, 2002)
"We studied the tolerance and pharmacokinetic parameters of ciprofloxacin in (2 mg/kg, i."	1.30	Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI). ( Barberi, I; De Sarro, A; Masaracchio, A; Naccari, F; Salpietro, DC, 1998)
"Ciprofloxacin was evaluated along with other commonly used antibiotics against a total of 425 clinical isolates obtained from urine samples."	1.30	Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Bangladesh. ( Iqbal, J; Kabir, MS; Rahman, M, 1997)
" coli develop in the presence of long-term selective ciprofloxacin pressure at a dosing regimen of 250 mg bid for more than 20 days and that treatment with a broad spectrum antimicrobial for more than three days favours the selection of multi-resistant E."	1.30	Molecular epidemiology of multi-resistant Escherichia coli. ( Barrett, SP; Cheasty, T; Guyot, A; Hampton, MD; Threlfall, EJ, 1999)
"We report a patient with polycystic renal disease and diabetes mellitus who developed a urinary infection due to Salmonella enteritidis following presumed enteric infection."	1.29	Salmonella enteritidis urinary infection associated with polycystic renal disease. ( Douglas, JG; Laing, RB; Smith, FW, 1993)
"Ciprofloxacin was started on postoperative day 13 for treatment of a urinary tract infection."	1.28	Fulminant hepatic failure possibly related to ciprofloxacin. ( Grassmick, BK; Lehr, VT; Sundareson, AS, 1992)
"Against respiratory tract infections with K."	1.28	In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ( Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y, 1991)
"Intravenous ciprofloxacin at a daily dosage of 400 mg divided in two doses was administered to 19 patients with severe infections caused by ciprofloxacin-susceptible bacteria."	1.28	Intravenous ciprofloxacin for the treatment of severe infections. ( Baiocchi, P; Brandimarte, C; Gelfusa, V; Santini, C; Serra, P; Tarasi, A; Venditti, M, 1991)
"Ciprofloxacin was found to be the most active drug tested against all gram-negative organisms and streptococci, with the exception of Streptococcus faecalis and Streptococcus pneumoniae."	1.27	Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy. ( Hoogkamp-Korstanje, JA, 1984)
"Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h."	1.27	In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ( Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988)
"Ciprofloxacin is an effective and safe therapeutic alternative in many tissue infections caused by susceptible microorganisms."	1.27	Open, prospective study of the clinical efficacy of ciprofloxacin. ( Bran, JL; Garcia, JF; Mejia, CR; Ramirez, CA, 1985)
" Adverse reactions were spontaneously reported by four of the 28 patients (14%) and by 11 (39%) after detailed inquiry."	1.27	Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. ( Boerema, J; Boll, B; Branolte, J; Muytjens, H, 1985)
" There were no significant differences in serum Tmax (1."	1.27	Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. ( Ball, AP; Ball, ME; Brown, IR; Fox, C; Willis, JV, 1986)
"Fleroxacin is a potent quinolone with in-vitro activity against a variety of resistant bacterial species."	1.27	In-vitro activity of fleroxacin against urinary tract and genital tract pathogens. ( Dubois, J; Fontaine, V, 1988)
"Ciprofloxacin was the most active agent."	1.27	In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species. ( Allocati, N; Cellini, L; Di Girolamo, A; Piccolomini, R; Scazzocchio, F; Selan, L, 1988)
"Ciprofloxacin is a new quinolone antimicrobial agent with activity against a broad spectrum of gram-negative and gram-positive organisms, including Pseudomonas aeruginosa and methicillin-resistant strains of staphylococci."	1.27	A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial. ( Arcieri, G; August, R; Becker, N; Griffith, E; Gruenwaldt, G; Heyd, A; O'Brien, B; Screen, P, 1988)
"Ciprofloxacin (Bay o9867) is a new quinolone derivative."	1.27	Comparative "in vitro" activity of ciprofloxacin (Bay o9867) and other antimicrobial agents against urinary bacterial isolates. ( Piccolomini, R; Ravagnan, G, 1986)
" Depending on renal function the dosage varied from 100 mg once daily to 250 mg twice daily."	1.27	The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection. ( Brown, EM; Morris, R; Stephenson, TP, 1986)

Research

Studies (623)

Authors

Clinical Trials (18)

Trial Overview

Trial Outcomes

Percentage of Participants With Microbiologic Success

Timeframe	Studies, this research(%)	All Research%
pre-1990	85 (13.64)	18.7374
1990's	114 (18.30)	18.2507
2000's	173 (27.77)	29.6817
2010's	191 (30.66)	24.3611
2020's	60 (9.63)	2.80

Authors	Studies
Takeda, S	1
Nakai, T	1
Wakai, Y	1
Ikeda, F	1
Hatano, K	1
Sevillano, D	1
Aguilar, L	1
Alou, L	1
Giménez, MJ	1
Torrico, M	1
González, N	1
Cafini, F	1
Relaño, MT	1
Coronel, P	1
Prieto, J	1
Prakash, V	1
Lewis, JS	1
Herrera, ML	1
Wickes, BL	1
Jorgensen, JH	1
Allou, N	1
Cambau, E	1
Massias, L	1
Chau, F	1
Fantin, B	1
Peirano, G	1
Richardson, D	1
Nigrin, J	1
McGeer, A	1
Loo, V	1
Toye, B	1
Alfa, M	2
Pienaar, C	1
Kibsey, P	1
Pitout, JD	1
Blango, MG	1
Mulvey, MA	1
Auer, S	1
Wojna, A	1
Hell, M	1
Jiang, X	2
Abgottspon, D	2
Kleeb, S	2
Rabbani, S	2
Scharenberg, M	2
Wittwer, M	1
Haug, M	1
Schwardt, O	2
Ernst, B	2
Pang, L	1
Mayer, K	1
Eris, D	1
Sigl, A	1
Preston, RC	1
Zihlmann, P	1
Sharpe, T	1
Jakob, RP	1
Hutter, AS	1
Navarra, G	1
Smiesko, M	1
Lüdin, N	1
Bezençon, J	1
Maier, T	1
Rahuman, HBH	1
Dhandapani, R	1
Palanivel, V	1
Thangavelu, S	1
Paramasivam, R	1
Muthupandian, S	1
Lignieres, G	1
Birgy, A	1
Jung, C	1
Bonacorsi, S	1
Levy, C	1
Angoulvant, F	1
Grimprel, E	1
Dommergues, MA	1
Gillet, Y	1
Craiu, I	1
Rybak, A	1
De Pontual, L	1
Dubos, F	1
Cixous, E	1
Gajdos, V	1
Pinquier, D	1
Andriantahina, I	1
Soussan-Banini, V	1
Georget, E	1
Launay, E	1
Vignaud, O	1
Cohen, R	1
Madhi, F	1
Kerkez, I	1
Tulkens, PM	1
Tenson, T	1
Van Bambeke, F	1
Putrinš, M	1
Ur Rehman, J	1
Iqbal, A	1
Mahmood, A	1
Muhammad Asif, H	1
Mohiuddin, E	1
Akram, M	1
Mumtaz, K	1
Munir, S	1
Muddassir, M	1
Raza, A	1
Waqas, K	1
Shoaib Ahmed, S	1
Malik, A	1
Haider Naqvi, SZ	1
Xue, Z	1
Xiang, Y	1
Li, Y	1
Yang, Q	1
Ten Doesschate, T	2
Kuiper, S	1
van Nieuwkoop, C	4
Hassing, RJ	1
Ketels, T	1
van Mens, SP	2
van den Bijllaardt, W	1
van der Bij, AK	1
Geerlings, SE	3
Koster, A	1
Koldewijn, EL	1
Branger, J	1
Hoepelman, AIM	2
van Werkhoven, CH	1
Bonten, MJM	2
Teakell, JM	1
Molony, DA	1
Dobbyn, D	1
Zeggil, T	1
Kudrowich, B	1
Beahm, NP	1
Benavides, TM	1
Aden, JK	1
Giancola, SE	1
Derakhshan, S	1
Ahmadi, S	1
Ahmadi, E	1
Nasseri, S	1
Aghaei, A	1
Fuchs, F	1
Becerra-Aparicio, F	1
Xanthopoulou, K	1
Seifert, H	1
Higgins, PG	1
Carmona-Cartaya, Y	1
Hidalgo-Benito, M	1
Borges-Mateus, LM	1
Pereda-Novales, N	1
González-Molina, MK	1
Quiñones-Pérez, D	1
Frisbie, L	1
Weissman, SJ	1
Kapoor, H	1
D'Angeli, M	1
Salm, A	1
Radcliff, J	1
Rabinowitz, P	1
Jalil, MB	1
Al Atbee, MYN	1
Salm, J	2
Salm, F	2
Arendarski, P	2
Kramer, TS	2
Prasada Rao, CMM	1
Vennila, T	1
Kosanam, S	1
Ponsudha, P	1
Suriyakrishnaan, K	1
Alarfaj, AA	1
Hirad, AH	1
Sundaram, SR	1
Surendhar, PA	1
Selvam, N	1
Davis, WH	1
Magee, MR	1
Monks, SM	1
Geno, KA	1
Crawford, SB	1
Danneels, P	1
Rihet, C	1
Vannier, C	1
Quinqueneau, C	1
Courtois, R	1
Kempf, M	1
Eveillard, M	1
Mahieu, R	1
Dubée, V	1
Dunne, MW	2
Aronin, SI	2
Das, AF	2
Akinapelli, K	2
Breen, J	1
Zelasky, MT	2
Puttagunta, S	2
Boucher, HW	1
Wang, J	1
Gagne, JJ	1
Kattinakere-Sreedhara, S	1
Fischer, MA	1
Bykov, K	1
Mohseni, M	1
Craver, EC	1
Heckman, MG	1
Sheele, JM	1
Keuler, N	1
Johnson, Y	1
Coetzee, R	1
Owusu, H	1
Thekkur, P	1
Ashubwe-Jalemba, J	1
Hedidor, GK	1
Corquaye, O	1
Aggor, A	1
Steele-Dadzie, A	1
Ankrah, D	1
Wildermuth, A	1
Holmes, M	1
Sadeq Al-Ethari, A	1
Hayder Hasan, T	1
Abbas Tikki, K	1
Sabah Bustani, G	1
Maki N Al-Muaala, A	1
Sadeq Yasir Al-Ethari, A	1
Abdul Ameer Al-Kraety, I	1
Ghani Al-Muhanna, S	1
Frimodt-Møller, N	5
Simonsen, GS	3
Larsen, AR	3
Kahlmeter, G	3
Abbott, IJ	2
van Gorp, E	2
Cottingham, H	2
Macesic, N	2
Wallis, SC	2
Roberts, JA	2
Meletiadis, J	2
Peleg, AY	2
Barnawi, MH	1
Thabit, AK	1
Almasri, DM	1
Bulbol, S	1
Ruijuan, Z	1
Li, X	1
Yingjie, W	1
Rui, W	1
Chunqing, L	1
Whelan, S	1
O'Grady, MC	2
Corcoran, GD	2
Finn, K	1
Lucey, B	2
Hamid, K	1
Hamza, M	1
Naim, T	1
Shahid, M	1
Hsu, JL	1
Lee, HG	1
Seo, Y	1
Kim, JH	1
Han, SB	1
Im, JH	1
Jung, CY	1
Durey, A	1
Valentine-King, M	1
Zoorob, R	1
Grigoryan, L	1
Trautner, B	2
Mekonnen, S	1
Tesfa, T	1
Shume, T	1
Tebeje, F	1
Urgesa, K	1
Weldegebreal, F	1
Araújo, MRB	1
Sant'Anna, LO	1
Santos, NNCD	1
Seabra, LF	1
Santos, LSD	1
Afsharikhah, S	1
Ghanbarpour, R	1
Mohseni, P	1
Adib, N	1
Bagheri, M	1
Jajarmi, M	1
Sheikh, RY	1
Murdeshwar, S	1
Maheshwari, TK	1
Chacko, S	1
Mouanga-Ndzime, Y	1
Onanga, R	1
Longo-Pendy, NM	1
Bignoumba, M	1
Bisseye, C	1
Mosonik, GC	1
Kombich, JJ	1
Koh, SWC	1
Ng, TSM	1
Loh, VWK	1
Goh, JC	1
Low, SH	1
Tan, WZ	1
Wong, HC	1
Durai, P	1
Sun, LJ	1
Young, D	1
Tambyah, PA	1
Kim, C	1
Choi, YH	1
Choi, JY	2
Choi, HJ	2
Park, RW	1
Rhie, SJ	1
Damavand, RS	1
Esmaeili, S	1
Bateni, BH	1
Tavakoli, AA	1
Kazemnezhad, E	1
Sugathan, S	1
Mandal, J	2
Zisman, A	1
Badaan, S	1
Kastin, A	1
Kravtsov, A	1
Amiel, GE	1
Mullerad, M	1
Kotb, DN	1
Mahdy, WK	1
Mahmoud, MS	1
Khairy, RMM	1
Hozzari, A	1
Behzadi, P	1
Kerishchi Khiabani, P	1
Sholeh, M	1
Sabokroo, N	1
Usta, J	1
Araj, G	1
Taleb, R	1
Reniguntla, MK	1
Yedle, R	1
Puttaswamy, R	1
Puttarangappa, P	1
Hiremath, S	1
Pawar, A	1
Nanjundappa, M	1
Jayaraman, R	1
Cai, T	3
Palagin, I	1
Brunelli, R	1
Cipelli, R	1
Pellini, E	1
Truzzi, JC	1
Van Bruwaene, S	1
Monteiro-Neto, V	1
de Souza, CD	1
Gonzaga, LF	1
da Silveira, BC	1
Sousa, NCF	1
Pontes, JP	1
Santos, DM	1
Martins, WC	1
Pessoa, JFV	1
Carvalho Júnior, AR	1
Almeida, VSS	1
de Oliveira, NMT	1
de Araújo, TS	1
Maria-Ferreira, D	1
Mendes, SJF	1
Ferro, TAF	1
Fernandes, ES	1
Casanovas Moreno-Torres, MI	1
Rodríguez-Campos, F	1
Gutiérrez-Soto, M	1
Navarro-Marí, JM	1
Gutiérrez-Fernández, J	1
Stompór, T	1
Demirci-Duarte, S	1
Unalan-Altintop, T	1
Eser, OK	1
Cakar, A	1
Altun, B	1
Sancak, B	1
Gur, D	1
Stapleton, AE	1
Wagenlehner, FME	2
Mulgirigama, A	1
Twynholm, M	1
González, MJ	1
Zunino, P	1
Scavone, P	1
Robino, L	1
Tekalign, TG	1
Shiferaw, MS	1
Hailegiyorgis, TT	1
Embiale, YB	1
Abebe, FA	1
Ehdaie, B	1
Jibara, G	1
Sjoberg, DD	1
Laudone, V	1
Eastham, J	1
Touijer, K	2
Scardino, P	1
Donahue, T	1
Goh, A	1
Vickers, A	1
Drekonja, DM	2
Amundson, C	1
Kuskowski, M	1
Johnson, JR	2
van der Starre, WE	1
Stalenhoef, JE	1
van Aartrijk, AM	1
van der Reijden, TJ	1
Vollaard, AM	1
Delfos, NM	2
van 't Wout, JW	1
Blom, JW	2
Spelt, IC	2
Leyten, EM	2
Koster, T	2
Ablij, HC	2
van der Beek, MT	1
Knol, MJ	1
van Dissel, JT	2
Kistler, CE	2
Zimmerman, S	2
Scales, K	1
Ward, K	2
Weber, D	1
Reed, D	1
McClester, M	1
Sloane, PD	2
Grodin, L	1
Conigliaro, A	1
Lee, SY	1
Rose, M	1
Sinert, R	1
Moreira da Silva, RCR	1
de Oliveira Martins Júnior, P	1
Gonçalves, LF	1
de Paulo Martins, V	1
de Melo, ABF	1
Pitondo-Silva, A	1
de Campos, TA	1
Gökçe, İ	1
Çiçek, N	1
Güven, S	1
Altuntaş, Ü	1
Bıyıklı, N	1
Yıldız, N	1
Alpay, H	1
Seitz, M	1
Stief, C	1
Waidelich, R	1
Bader, M	1
Tilki, D	1
Zembower, TR	1
Maxwell, KM	1
Nadler, RB	1
Cashy, J	1
Scheetz, MH	1
Qi, C	1
Schaeffer, AJ	3
Magyar, A	1
Köves, B	1
Nagy, K	1
Dobák, A	1
Arthanareeswaran, VKA	1
Bálint, P	1
Wagenlehner, F	2
Tenke, P	1
Edson, RS	1
Litin, SC	1
Bundrick, JB	1
Altobelli, E	1
Mohan, R	1
Mach, KE	1
Sin, MLY	1
Anikst, V	1
Buscarini, M	1
Wong, PK	2
Gau, V	1
Banaei, N	1
Liao, JC	2
Costa, T	1
Linhares, I	1
Ferreira, R	1
Neves, J	1
Almeida, A	1
Cavallone, B	1
Serao, A	1
Audino, P	1
Di Stasio, A	1
Tiranti, D	1
Vota, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults[NCT03357614]	Phase 3	1,395 participants (Actual)	Interventional	2018-09-18	Completed
Seven Versus Fourteen Day Treatment for Male Urinary Tract Infection[NCT01994538]		273 participants (Actual)	Interventional	2014-04-24	Completed
Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With [NCT00809913]	Phase 4	200 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486]		1,257 participants (Actual)	Interventional	2017-05-31	Completed
Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)[NCT01659866]	Phase 4	563 participants (Actual)	Interventional	2012-08-31	Completed
A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.[NCT01928433]	Phase 2	225 participants (Actual)	Interventional	2012-12-31	Completed
Epidemiology of ST131 in Besançon University Hospital[NCT02853708]		300 participants (Actual)	Observational	2015-06-30	Completed
The Impact of the Implementation of Academic Detailing Interventions Based on Scientific Evidence on the Prescribing of Antimicrobial Drugs in Primary Health Care[NCT05090475]		16 participants (Actual)	Interventional	2020-04-01	Completed
A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis[NCT00210886]	Phase 3	1,109 participants (Actual)	Interventional	2004-10-31	Completed
[NCT02729116]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
Treatment of Febrile Infectious Disease Among Children in Hadera District Given the Final Diagnosis. Descriptive Study[NCT02313532]		500 participants (Anticipated)	Observational	2015-01-31	Not yet recruiting
Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study[NCT02591901]	Phase 2	48 participants (Actual)	Interventional	2018-04-06	Completed
Neutrophil and Lymphocyte Counts and the Neutrophil-to-lymphocyte Ratio as a Predictor of Fever Following Percutaneous Nephrolithotomy in Patients Without Risk Factors[NCT03774940]		519 participants (Actual)	Interventional	2005-01-01	Completed
The Preventive Urinary Tract Infection Role of One Week Solutions of Antimicrobial Application Before Minimally Invasive Upper Tract Lithotomy[NCT02789579]	Early Phase 1	150 participants (Anticipated)	Interventional	2016-09-30	Recruiting
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer: a Phase III Randomized Trial[NCT03862170]	Phase 3	255 participants (Anticipated)	Interventional	2015-02-10	Suspended (stopped due to Covid-19 pandemic)
Prevention of UTI in Persons With Spinal Cord Injury[NCT00309114]		65 participants (Actual)	Interventional	2004-02-29	Completed
Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial[NCT03287089]	Phase 4	164 participants (Actual)	Interventional	2017-09-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Microbiologic success is defined as demonstrating <1000 CFU/mL of the baseline urpathogen by quantitative urine culture (NCT03357614)
Timeframe: Day 21 +/- 1 day

Percentage of Participants With Overall Success

Intervention	Participants (Count of Participants)
Sulopenem	316
Ertapenem	343

Clinical success is defined as complete resolution of cUTI symptoms present at study entry and no new cUTI symptoms; microbiologic success is defined as eradication of the bacterial pathogen found at study entry (reduced to <1000 CFU/mL) (NCT03357614)
Timeframe: Day 21 +/- 1 day

Adverse Drug Event in the 28 Days After Completing Study Medication

Intervention	Participants (Count of Participants)
Sulopenem	301
Ertapenem	325

"The incidence of adverse drug events, including nausea, vomiting, diarrhea, dizziness, headache, drug allergy, and C. difficile infection, both individually and in aggregate, will be compared between treatment groups~This outcome is number of subjects experiencing ANY adverse drug event" (NCT01994538)
Timeframe: 28 days

Intestinal Carriage of Antimicrobial-resistant Gram Negative Bacilli

Intervention	Participants (Count of Participants)
Longer (14 Day) Duration Antimicrobial Treatment	29
Shorter (7 Day) Duration Antimicrobial Treatment	26

Intestinal carriage of antimicrobial-resistant Gram-negative bacilli after completing study medication, as compared to a baseline sample taken early in treatment. Antimicrobial resistance for this measure was defined as newly detected resistance to either of the study drugs, ciprofloxacin or trimethoprim/sulfamethoxazole. (NCT01994538)
Timeframe: 7 days

Recurrent UTI Within 28 Days of Completing Active Study Medication

Intervention	Participants (Count of Participants)
Longer (14 Day) Duration Antimicrobial Treatment	4
Shorter (7 Day) Duration Antimicrobial Treatment	4

New onset of symptomatic UTI within the 28 day follow-up period (NCT01994538)
Timeframe: 28 days

Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy

Intervention	Participants (Count of Participants)
Longer (14 Day) Duration Antimicrobial Treatment	15
Shorter (7 Day) Duration Antimicrobial Treatment	13

This outcome will be assessed in a binary manner. Subjects with persistent UTI symptoms or having received further antimicrobials because of UTI symptoms will be considered to have not met the primary outcome, whereas those without persistent UTI symptoms and not having received further antimicrobials will be considered to have met the primary outcome. (NCT01994538)
Timeframe: 14 days

Number of Participants With Post-biopsy Infection.

Intervention	Participants (Count of Participants)
Longer (14 Day) Duration Antimicrobial Treatment	111
Shorter (7 Day) Duration Antimicrobial Treatment	122

To measure and compare the rates of infection following TRUSP in subjects with and without CR-GNB. This measure is number of participants with post-biopsy infection. (NCT01659866)
Timeframe: 30 days post-biopsy

Number of Participants With Clinical and Microbiological Response

Intervention	participants (Number)
Cipro-susceptible	6
Cipro-resistant	3

"The primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).~Clinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group." (NCT01928433)
Timeframe: Day 17

Number of Participants With Clinical and Microbiological Response at the End of Study (EoS) Visit (Day 24).

Intervention	Participants (Count of Participants)
Finafloxacin 5 Days	45
Finafloxacin 10 Days	46
Ciprofloxacin 10 Days	35

The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 24

Number of Participants With Clinical and Microbiological Response at the End of Therapy (EoT) Visit (Day 10).

Intervention	Participants (Count of Participants)
Finafloxacin 5 Days	47
Finafloxacin 10 Days	42
Ciprofloxacin 10 Days	34

Number of Participants With Clinical and Microbiological Response at the On Therapy (OT) Visit (Day 3).

Intervention	Participants (Count of Participants)
Finafloxacin 5 Days	49
Finafloxacin 10 Days	49
Ciprofloxacin 10 Days	44

The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Participants Who Discontinued Due to TEAE

Intervention	Participants (Count of Participants)
Finafloxacin 5 Days	39
Finafloxacin 10 Days	40
Ciprofloxacin 10 Days	33

This study will evaluate the safety of the different regimens of finafloxacin. The safety outcome measures assessed are the following: vital signs, physical examinations, ECGs, haematology, biochemistry, urinalysis, adverse events and serious adverse events. Adverse events and serious adverse events will be documented throughout the study for each group (including comparator group and the incidence and severity of their occurrence will be compared between all groups. The results of all other safety outcome measures will be compared with the baseline values of each group to determine if significant changes occurred during the course of the study within one group. The results at the different visits will also be compared between the groups to identify significant differences between the 3 treatment groups. (NCT01928433)
Timeframe: Screening to day 24

The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Treatment-emergent Adverse Events

Intervention	Participants (Count of Participants)
Finafloxacin 5 Days	7
Finafloxacin 10 Days	2
Ciprofloxacin 10 Days	4

Medication Compliance

Intervention	Treatment-emergent AEs (Number)
Finafloxacin 5 Days	70
Finafloxacin 10 Days	51
Ciprofloxacin 10 Days	70

Compliance assessed by use of a medication diary during treatment period (NCT03287089)
Timeframe: within 30 days of surgery

UTI

Intervention	ratio (Mean)
Nitrofurantoin	0.95
Placebo	0.96

Number of participants with a urinary tract infection in the first 30 days following pelvic reconstructive surgery (NCT03287089)
Timeframe: within 30 days of surgery

Article	Year
A systematic review and meta-analysis of levofloxacin and ciprofloxacin in the treatment of urinary tract infection. Annals of palliative medicine, 2021, Volume: 10, Issue:9 Topics: Ciprofloxacin; Humans; Levofloxacin; Urinary Tract Infections	2021
Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review. Antimicrobial agents and chemotherapy, 2020, 09-21, Volume: 64, Issue:10 Topics: Anti-Bacterial Agents; Asia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacteria	2020
Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World journal of urology, 2018, Volume: 36, Issue:3 Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy, Large-Core Needle; Ciproflo	2018
[Treatment of vancomycin-resistant enterococcal infections]. Ugeskrift for laeger, 2018, Apr-16, Volume: 180, Issue:16 Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Daptomycin; Denmark; Drug Therapy, Combination; Gr	2018
The perils of prescribing fluoroquinolones. The Journal of family practice, 2013, Volume: 62, Issue:4 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Prescriptions; Female; Fluoroquinolones; Humans; Middle A	2013
Evaluation of antimicrobial susceptibility of Enterobacteriaceae causing urinary tract infections in Africa. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8 Topics: Africa; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Databases, Factual; Drug Ev	2013
Use of ciprofloxacin during breastfeeding. Canadian family physician Medecin de famille canadien, 2015, Volume: 61, Issue:4 Topics: Adult; Animals; Bone Development; Breast Feeding; Child Development; Ciprofloxacin; Female; Fluoroqu	2015
Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC infectious diseases, 2015, Nov-25, Volume: 15 Topics: Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Esc	2015
Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ (Clinical research ed.), 2016, Mar-15, Volume: 352 Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Child; Child, Preschool; Cipro	2016
[Lower urinary tract infections: bacterial epidemiology and recommendations]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:1 Suppl FM Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Ag	2008
Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. International journal of clinical pharmacology and therapeutics, 2009, Volume: 47, Issue:5 Topics: Anti-Infective Agents; Ciprofloxacin; Electroencephalography; Female; Humans; Risk Factors; Seizures	2009
[Infectious diseases]. Revue medicale suisse, 2013, Jan-09, Volume: 9, Issue:368 Topics: Anti-Bacterial Agents; Ciprofloxacin; Diabetic Foot; Endocarditis; Humans; Infections; Plant Extract	2013
The expanding role of fluoroquinolones. The American journal of medicine, 2002, Jul-08, Volume: 113 Suppl 1A Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Ga	2002
Pediatric urinary tract infections: the role of fluoroquinolones. The Pediatric infectious disease journal, 2003, Volume: 22, Issue:12 Topics: Age Factors; Child; Child, Preschool; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administ	2003
Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis. Drugs & aging, 2004, Volume: 21, Issue:1 Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Delayed-Action Preparations; Gram-Negati	2004
Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. Drugs, 2004, Volume: 64, Issue:6 Topics: Anti-Infective Agents; Ciprofloxacin; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Re	2004
Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. International journal of antimicrobial agents, 2004, Volume: 23 Suppl 1 Topics: Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Escherichia coli Infections; Trime	2004
Levofloxacin in the treatment of urinary tract infections and prostatitis. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 2 Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug	2004
The treatment of urinary tract infections and use of ciprofloxacin extended release. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:5 Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Delayed-Action Preparations; Female; Humans; Urinary	2006
Resistance in gram-negative bacteria: enterobacteriaceae. The American journal of medicine, 2006, Volume: 119, Issue:6 Suppl 1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Ciprofloxacin; Community-	2006
[Bacterial infections in liver cirrhosis]. Orvosi hetilap, 2007, Mar-04, Volume: 148, Issue:9 Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites;	2007
[New prospects in the treatment of urinary tract infections with modified-release ciprofloxacin]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2006, Volume: 78, Issue:3 Suppl 1 Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Clinical Trials, Phase III as Topic; D	2006
Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs & aging, 1994, Volume: 4, Issue:2 Topics: Bacterial Infections; Ciprofloxacin; Drug Interactions; Humans; Premedication; Respiratory Tract Inf	1994
Fluoroquinolones reviewed. Drug and therapeutics bulletin, 1993, Aug-31, Volume: 31, Issue:18 Topics: Adult; Anti-Infective Agents; Child; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Norflo	1993
Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. The Journal of urology, 1997, Volume: 157, Issue:6 Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Humans; Male; Middle A	1997
[Current role of aminoglycosides in the treatment of acute pyelonephritis]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1998, Volume: 8, Issue:6 Topics: Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefadroxil	1998
Quinolones: a comprehensive review. American family physician, 2002, Feb-01, Volume: 65, Issue:3 Topics: Ciprofloxacin; Drug Interactions; Humans; Male; Prostatitis; Quinolones; Respiratory Tract Diseases;	2002
Do we need an intravenous fluoroquinolone? The Western journal of medicine, 1992, Volume: 157, Issue:1 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Drug Resistance, Microbial; Gram-Negative B	1992
Laryngeal edema related to ciprofloxacin therapy. The Annals of pharmacotherapy, 1992, Volume: 26, Issue:11 Topics: Aged; Aged, 80 and over; Ciprofloxacin; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Del	1992
[A review of clinical studies on the efficacy and tolerance of intravenous ciprofloxacin]. Recenti progressi in medicina, 1992, Volume: 83, Issue:1 Topics: Ciprofloxacin; Clinical Trials as Topic; Drug Tolerance; Humans; Injections, Intravenous; Respirator	1992
Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. The Journal of antimicrobial chemotherapy, 1990, Volume: 26 Suppl F Topics: Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Osteomyelitis; Pseudomonas aerug	1990
Acute renal failure due to ciprofloxacin. Archives of internal medicine, 1990, Volume: 150, Issue:10 Topics: Acute Kidney Injury; Adult; Aged; Biopsy; Ciprofloxacin; Erythema Multiforme; Female; Humans; Kidney	1990
Ciprofloxacin as treatment for genitourinary tract infection. The Journal of urology, 1989, Volume: 141, Issue:1 Topics: Bacterial Infections; Ciprofloxacin; Female; Genital Diseases, Female; Genital Diseases, Male; Human	1989
Clinical impact of newer quinolones: influence on normal microflora. Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:1 Topics: Bacterial Infections; Ciprofloxacin; Humans; Immune Tolerance; Intestinal Mucosa; Norfloxacin; Oroph	1989
Ciprofloxacin in urinary tract infections. Scandinavian journal of infectious diseases. Supplementum, 1989, Volume: 60 Topics: Bacteria; Ciprofloxacin; Clinical Trials as Topic; Costs and Cost Analysis; Female; Humans; Male; Ur	1989
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrobial agents and chemotherapy, 1985, Volume: 28, Issue:5 Topics: Anti-Bacterial Agents; Bacteria; Blood Proteins; Ciprofloxacin; Enoxacin; Fluorine; Humans; Kidney;	1985
Overview of clinical experience with ciprofloxacin. European journal of clinical microbiology, 1986, Volume: 5, Issue:2 Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enteritis; Enterob	1986
Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review. Infection, 1988, Volume: 16, Issue:6 Topics: Adult; Aged; Bacteriuria; Ciprofloxacin; Enterobacteriaceae Infections; Female; Humans; Male; Microb	1988
Ciprofloxacin in management of urinary tract infection. Urology, 1988, Volume: 31, Issue:4 Topics: Bacterial Infections; Ciprofloxacin; Humans; Male; Microbial Sensitivity Tests; Prostatitis; Urinary	1988
The role of 4-quinolones in the treatment of infections. Comprehensive therapy, 1987, Volume: 13, Issue:2 Topics: Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Norfloxacin; Ofloxacin; Oxazines; Urinary Tra	1987
New approaches to the treatment of urinary tract infection. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Pyelonephritis; Ur	1987

Article	Year
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-25, Volume: 75, Issue:2 Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; COVID-19; Double-Blind Method; Escherichia coli; Escher	2022
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 01-06, Volume: 76, Issue:1 Topics: Adult; Anti-Bacterial Agents; Bacteriuria; Ciprofloxacin; Ertapenem; Humans; Pyelonephritis; Urinary	2023
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 01-06, Volume: 76, Issue:1 Topics: Anti-Bacterial Agents; Ciprofloxacin; Female; Humans; Lactams; Urinary Tract Infections	2023
Effects of Catheter Tracking Management on Urinary Tract Function and Infection Rates in Patients With Spinal Cord Injury. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:3 Topics: Anti-Bacterial Agents; Catheters; Ciprofloxacin; Gentamicins; Humans; Levofloxacin; Piperacillin; Qu	2023
Comparing the effect of peri-operative antibiotic prophylaxis only with continuous low-dose antibiotic treatment on the incidence of urinary tract infection and stent related-symptoms in patients undergoing Double-J (DJ) stent insertion following transure World journal of urology, 2023, Volume: 41, Issue:11 Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Humans; Incidence; Lithotripsy; Stents	2023
The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial. The Journal of urology, 2021, Volume: 206, Issue:3 Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Catheter-Related Infections; Catheters; Ciprofl	2021
Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. JAMA, 2021, 07-27, Volume: 326, Issue:4 Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Durat	2021
Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC medicine, 2017, Apr-03, Volume: 15, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule	2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac	2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac	2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac	2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac	2017
Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:4 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin	2018
Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial. World journal of urology, 2018, Volume: 36, Issue:11 Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Large-Core Needle; Bloo	2018
Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST). BMC infectious diseases, 2018, Dec-05, Volume: 18, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-	2018
Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial. Urologic oncology, 2019, Volume: 37, Issue:3 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Catheter-Related Infectio	2019
Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults. Urologia internationalis, 2019, Volume: 102, Issue:4 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chemotherapy, Adjuvant; Ciprofloxacin; Double-Blind	2019
[A multicenter comparative observation on the effectiveness and the rapidness of the effect of Cystostop Rapid versus antibiotic therapy in patients with uncomplicated cystitis]. Akusherstvo i ginekologiia, 2012, Volume: 51, Issue:7 Topics: Adolescent; Adult; Anti-Bacterial Agents; Betula; Ciprofloxacin; Cystitis; Female; Humans; Mannose;	2012
Single-dose versus multiple-dose ciprofloxacin plus metronidazole prophylaxis in transrectal ultrasound-guided biopsy of the prostate: a randomized controlled trial. Acta medica Iranica, 2014, Volume: 52, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial	2014
A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Urologia internationalis, 2016, Volume: 97, Issue:3 Topics: Acute Disease; Adult; Anti-Bacterial Agents; Capsules; Ciprofloxacin; Cystitis; Double-Blind Method;	2016
Is ciprofloxacin safe in patients with solitary kidney and upper urinary tract infection? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 84 Topics: Acetylglucosaminidase; Alpha-Globulins; Ciprofloxacin; Female; Glomerular Filtration Rate; Humans; K	2016
Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. International journal of urology : official journal of the Japanese Urological Association, 2008, Volume: 15, Issue:11 Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Ceftriaxone; Ciprofloxacin; Hum	2008
Antibiotic prophylaxis at urinary catheter removal prevents urinary tract infections: a prospective randomized trial. Annals of surgery, 2009, Volume: 249, Issue:4 Topics: Aged; Antibiotic Prophylaxis; Catheter-Related Infections; Ciprofloxacin; Confidence Intervals; Devi	2009
Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC infectious diseases, 2009, Aug-19, Volume: 9 Topics: Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Double-Blind Method; Female; Fever; Gentamicins;	2009
Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections. Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:6 Topics: Administration, Oral; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Drug Administration	2009
Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial. BMC medicine, 2010, May-26, Volume: 8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Ste	2010
A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2010, Volume: 16, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Administration Schedule; Enterob	2010
[Immunotherapy and long-term chemoprophylaxis in prevention of recurrent urinary infections in women]. Vnitrni lekarstvi, 2010, Volume: 56, Issue:9 Suppl Topics: Adjuvants, Immunologic; Adult; Aged; Anti-Infective Agents; Antigens, Bacterial; Bacterial Vaccines;	2010
Practices, patients and (im)perfect data--feasibility of a randomised controlled clinical drug trial in German general practices. Trials, 2011, Apr-01, Volume: 12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Ste	2011
Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized double-blind placebo-controlled trial. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, Volume: 17, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteriuria; Catheter	2011
Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Archives of internal medicine, 2011, Jul-25, Volume: 171, Issue:14 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Capsules; Ciprofloxacin;	2011
[Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection]. Actas urologicas espanolas, 2013, Volume: 37, Issue:3 Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Administration Schedule; Fema	2013
Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. International journal of antimicrobial agents, 2002, Volume: 20, Issue:1 Topics: Administration, Oral; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Fluoroquinolones	2002
[Antibacterial prophylaxis of bacteriuria at transrectal multifocal prostatic biopsy]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:7 Topics: Administration, Topical; Anti-Infective Agents; Anti-Infective Agents, Local; Antibiotic Prophylaxis	2002
Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clinical therapeutics, 2002, Volume: 24, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Delayed-Action Preparations; Double-B	2002
Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scandinavian journal of infectious diseases, 2003, Volume: 35, Issue:1 Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Confidence Intervals; Dose-Response Relationship,	2003
[Antibiotic prophylaxis in transrectal prostate biopsy. Short-term vs. long-term therapy]. Der Urologe. Ausg. A, 2003, Volume: 42, Issue:1 Topics: Aged; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Cross Infection; Drug Administration Sc	2003
Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. The Journal of urology, 2004, Volume: 171, Issue:2 Pt 1 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Del	2004
Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Feb-17, Volume: 170, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Double-Blind Me	2004
Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. International journal of antimicrobial agents, 2004, Volume: 23 Suppl 1 Topics: Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule;	2004
Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. International journal of antimicrobial agents, 2004, Volume: 23, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Me	2004
Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:4 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Latin America; N	2004
A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Sep-01, Volume: 39, Issue:5 Topics: Acute Disease; Adult; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Enterobacter	2004
Prulifloxacin. Drugs, 2004, Volume: 64, Issue:19 Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxaci	2004
A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin. BJU international, 2004, Volume: 94, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Device Removal; Do	2004
Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urologia internationalis, 2005, Volume: 74, Issue:4 Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Double-Blind Method; Female; Fluoroqu	2005
Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:1 Topics: Acute Disease; Adolescent; Adult; Ciprofloxacin; Cystitis; Drug Resistance, Bacterial; Escherichia c	2005
Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Current medical research and opinion, 2005, Volume: 21, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Delayed-Action Prepara	2005
Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Ci	2005
[Clinical significance of antibiotic prophylaxis for transrectal prostate biopsy]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2001, Volume: 39, Issue:12 Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Drug Therapy, Combin	2001
Effectiveness of ciprofloxacin prophylaxis in preventing bacteriuria caused by urodynamic study: a blind, randomized study of 192 patients. Urology, 2006, Volume: 67, Issue:6 Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacteriuria; Ciprofloxacin; Diagnostic Techniques, Ur	2006
[Therapy of urinary tract infections in patients with diabetes mellitus]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2005, Volume: 50, Issue:8-9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Delayed-Action Preparations; Di	2005
One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. BJU international, 2006, Volume: 98, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Dilatation, Pathologic; Female	2006
A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis;	2006
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clinical therapeutics, 2007, Volume: 29, Issue:10 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ciprof	2007
Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. International journal of antimicrobial agents, 2008, Volume: 31, Issue:2 Topics: Acute Disease; Adult; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis	2008
Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa. Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Delayed-Action Preparations; D	2007
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 2008, Volume: 71, Issue:1 Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do	2008
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 2008, Volume: 71, Issue:1 Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do	2008
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 2008, Volume: 71, Issue:1 Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do	2008
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 2008, Volume: 71, Issue:1 Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do	2008
Experience with ciprofloxacin in vitro and in vivo. Arzneimittel-Forschung, 1984, Volume: 34, Issue:12 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections;	1984
Antibiotic prophylaxis for urodynamic testing in patients with spinal cord injury: a preliminary study. The Journal of hospital infection, 1994, Volume: 28, Issue:1 Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Female; Humans; Male; Middle	1994
[Antibacterial activity of ciprofloxacin in the urine during four days after a single 500 mg and 750 mg oral dose]. Pathologie-biologie, 1994, Volume: 42, Issue:6 Topics: Administration, Oral; Adult; Ciprofloxacin; Enterococcus faecalis; Escherichia coli; Female; Humans;	1994
Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Archives of internal medicine, 1995, Mar-13, Volume: 155, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Colony Count, Microbial; D	1995
Re: Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, crossover, placebo controlled study in patients with spinal cord lesion. The Journal of urology, 1994, Volume: 152, Issue:6 Pt 1 Topics: Ciprofloxacin; Cross-Over Studies; Humans; Prospective Studies; Randomized Controlled Trials as Topi	1994
[Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults]. Klinicheskaia meditsina, 1994, Volume: 72, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Humans; Mal	1994
[The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract]. Recenti progressi in medicina, 1994, Volume: 85, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Tolerance; Female; Humans;	1994
Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women. The Journal of urology, 1994, Volume: 152, Issue:1 Topics: Adult; Ciprofloxacin; Coitus; Female; Humans; Norfloxacin; Ofloxacin; Prospective Studies; Recurrenc	1994
Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. The Journal of urology, 1994, Volume: 151, Issue:1 Topics: Adult; Aged; Alanine Transaminase; Ciprofloxacin; Double-Blind Method; Feces; Female; Follow-Up Stud	1994
Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. The Journal of urology, 1993, Volume: 149, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Gram-Negative Bacterial Infect	1993
[Single dose therapy of uncomplicated urinary tract infections in women. Remission rates with ciprofloxacin in two prospective randomized comparative studies]. Fortschritte der Medizin, 1993, Jan-30, Volume: 111, Issue:3 Topics: Adult; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Hysterectomy; Middle Aged; Posto	1993
Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. The American journal of medicine, 1993, Mar-22, Volume: 94, Issue:3A Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Ciprofloxacin; Double-Blind Met	1993
A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI. Drugs, 1995, Volume: 49 Suppl 2 Topics: Aged; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Female; Humans; Male; Nursing H	1995
Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Scandinavian journal of urology and nephrology, 1996, Volume: 30, Issue:1 Topics: Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Combinations; Human	1996
Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. The Journal of antimicrobial chemotherapy, 1996, Volume: 37 Suppl A Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Escherichia coli Infec	1996
Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:3 Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Female; F	1996
The value of antibiotic prophylaxis during extracorporeal shock wave lithotripsy in the prevention of urinary tract infections in patients with urine proven sterile prior to treatment. European urology, 1997, Volume: 31, Issue:1 Topics: Administration, Oral; Anti-Infective Agents; Antibiotic Prophylaxis; Cefuroxime; Cephalosporins; Cip	1997
Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. The Journal of urology, 1997, Volume: 157, Issue:3 Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Coitus; Female; Follow-Up Studies; Humans;	1997
[A clinical study on combination therapy of antimicrobial agents for complicated urinary tract infection--with special reference to combination with clarithromycin]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1997, Volume: 88, Issue:6 Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Therapy, Co	1997
Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. The Journal of urology, 1997, Volume: 158, Issue:4 Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Drug Administration Schedule; Female; Fleroxacin; Humans	1997
Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clinical transplantation, 1997, Volume: 11, Issue:5 Pt 1 Topics: Administration, Oral; Adult; Anti-Infective Agents; Bacteriuria; Brazil; Candidiasis; Cause of Death	1997
Antibiotic prophylaxis in patients with urinary retention undergoing transurethral prostatectomy. Annales chirurgiae et gynaecologiae, 1997, Volume: 86, Issue:3 Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Ceftazidime; Cephalosporins; Ciprofloxacin; Hu	1997
[Efficacy and tolerance of a five day course of ciprofloxacin in the treatment of urinary tract infection in women. Multicenter study]. Revista medica de Chile, 1998, Volume: 126, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Drug Tolerance; Female; Humans; Middl	1998
Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Archives of internal medicine, 1999, Jan-11, Volume: 159, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents,	1999
A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. The American journal of medicine, 1999, Volume: 106, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary	1999
Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group. International journal of antimicrobial agents, 1999, Volume: 11, Issue:2 Topics: Anti-Infective Agents; Bacteriuria; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Mal	1999
A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl A Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Age	1999
Biofilm in complicated urinary tract infection. International journal of antimicrobial agents, 1999, Volume: 11, Issue:3-4 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Ciprofloxacin; Clarithromycin;	1999
Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. Clinical therapeutics, 1999, Volume: 21, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin	1999
Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1999, Volume: 18, Issue:11 Topics: Administration, Oral; Adult; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cross-Over Studies; Ent	1999
Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic surgery. Urology, 2000, Volume: 55, Issue:2 Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Cefazolin; Cephalosporins; Chi-Square Distribu	2000
Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU international, 2000, Volume: 85, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Chi-Square D	2000
Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2000, Volume: 19, Issue:5 Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Administ	2000
Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation. International journal of antimicrobial agents, 2001, Volume: 17, Issue:4 Topics: Administration, Oral; Adsorption; Anti-Infective Agents; Anti-Infective Agents, Urinary; Biofilms; C	2001
[Observational study of therapy compliance in the treatment of uncomplicated urinary tract infections of the urinary tract with 500 mg ciprofloxacin suspension]. Archivos espanoles de urologia, 2001, Volume: 54, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pa	2001
Pilot trial of bacterial interference for preventing urinary tract infection. Urology, 2001, Volume: 58, Issue:3 Topics: Adult; Antibiosis; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Female; Humans; Male	2001
[Tavanik effectiveness and safety in the treatment of urinary tract infection complications]. Klinicheskaia meditsina, 2001, Volume: 79, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Middle Aged; Of	2001
Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. Journal of the American Geriatrics Society, 2001, Volume: 49, Issue:12 Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective	2001
Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology, 2002, Volume: 59, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Drug Admi	2002
Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2002, Volume: 8, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Humans;	2002
A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clinical therapeutics, 2002, Volume: 24, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Double-Blind Metho	2002
Infecton is not specific for bacterial osteo-articular infective pathology. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Infectious; Child; Child, Preschool; Ciproflo	2002
Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. The Journal of family practice, 1992, Volume: 34, Issue:2 Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Humans; Middle Aged; Qu	1992
A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. The American journal of medicine, 1992, Apr-06, Volume: 92, Issue:4A Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; F	1992
Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. The Online journal of current clinical trials, 1992, Aug-11, Volume: Doc No 15 Topics: Adult; Aerosols; Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Kidn	1992
Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet (London, England), 1992, Apr-18, Volume: 339, Issue:8799 Topics: Adult; Aged; Aged, 80 and over; Bacteriuria; Ciprofloxacin; Female; Humans; Male; Middle Aged; Prosp	1992
Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection. Urology, 1992, Volume: 40, Issue:5 Topics: Ciprofloxacin; Drug Administration Schedule; Escherichia coli Infections; Female; Humans; Male; Midd	1992
Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scandinavian journal of infectious diseases, 1992, Volume: 24, Issue:5 Topics: Adult; Aged; Bacteremia; Cefuroxime; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male;	1992
Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clinic proceedings, 1992, Volume: 67, Issue:12 Topics: Adult; Aged; Ciprofloxacin; Double-Blind Method; Female; Humans; Male; Middle Aged; Prospective Stud	1992
Value of single-dose ciprofloxacin in the treatment of acute uncomplicated urinary tract infection in women. Drugs under experimental and clinical research, 1991, Volume: 17, Issue:10-11 Topics: Acute Disease; Adolescent; Adult; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule;	1991
[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. The Japanese journal of antibiotics, 1991, Volume: 44, Issue:7 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents,	1991
Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrobial agents and chemotherapy, 1991, Volume: 35, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Gentamicins; Humans; Metabolic	1991
Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clinical pharmacy, 1991, Volume: 10, Issue:1 Topics: Adult; Ceftazidime; Ciprofloxacin; Cross Infection; Double-Blind Method; Drug Evaluation; Humans; Pn	1991
Antibiotic prophylaxis in vaginal hysterectomy. Three doses of cefuroxime plus metronidazole versus one dose of ciprofloxacin. Pharmaceutisch weekblad. Scientific edition, 1990, Dec-14, Volume: 12, Issue:6A Topics: Adult; Aged; Aged, 80 and over; Cefuroxime; Ciprofloxacin; Drug Administration Schedule; Drug Therap	1990
Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Dr	1990
Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:4 Topics: Administration, Oral; Adult; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug;	1990
Comparison of three dosage regimens of ciprofloxacin in urinary tract infections. International urology and nephrology, 1990, Volume: 22, Issue:3 Topics: Adult; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Male; Time Factors; Urinary Trac	1990
Single-dose ciprofloxacin in the treatment of uncomplicated urinary tract infection in women. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1989, Volume: 8, Issue:12 Topics: Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Administration Sch	1989
Ciprofloxacin in urinary tract infections. Scandinavian journal of infectious diseases. Supplementum, 1989, Volume: 60 Topics: Bacteria; Ciprofloxacin; Clinical Trials as Topic; Costs and Cost Analysis; Female; Humans; Male; Ur	1989
Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group. The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ciprofloxacin; Female; H	1989
Ciprofloxacin versus amoxycillin/clavulanic acid in the treatment of urinary tract infections in general practice. The Journal of antimicrobial chemotherapy, 1989, Volume: 24, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ciprofloxacin; Clavulanic Ac	1989
Treatment of urinary tract infections with ciprofloxacin. Clinical therapeutics, 1988, Volume: 10, Issue:5 Topics: Adolescent; Adult; Aged; Bacterial Infections; Child; Ciprofloxacin; Female; Humans; Male; Middle Ag	1988
Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria. European journal of clinical microbiology, 1986, Volume: 5, Issue:2 Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Clinical Trials a	1986
Single dose, oral antibiotic cover for transurethral prostatectomy. British journal of urology, 1988, Volume: 62, Issue:5 Topics: Administration, Oral; Aged; Bacteriuria; Ciprofloxacin; Clinical Trials as Topic; Double-Blind Metho	1988
Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. The Journal of antimicrobial chemotherapy, 1988, Volume: 22 Suppl D Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Ciproflo	1988
Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. The Journal of antimicrobial chemotherapy, 1988, Volume: 22 Suppl C Topics: Ciprofloxacin; Double-Blind Method; Humans; Ofloxacin; Prospective Studies; Random Allocation; Urina	1988
Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. Antimicrobial agents and chemotherapy, 1988, Volume: 32, Issue:9 Topics: Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests;	1988
Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. Infection, 1988, Volume: 16 Suppl 1 Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Liver Diseases	1988
Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study. Infection, 1988, Volume: 16 Suppl 1 Topics: Adult; Bacterial Infections; Cephalexin; Ciprofloxacin; Clinical Trials as Topic; Humans; Random All	1988
Treatment of multi-resistant urinary tract infections in patients with multiple sclerosis. Pharmaceutisch weekblad. Scientific edition, 1987, Dec-11, Volume: 9 Suppl Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; M	1987
Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. The Journal of antimicrobial chemotherapy, 1986, Volume: 18 Suppl D Topics: Adult; Anti-Infective Agents, Urinary; Ciprofloxacin; Double-Blind Method; Drug Combinations; Female	1986
Ciprofloxacin and co-trimoxazole in urinary tract infection. The Journal of antimicrobial chemotherapy, 1986, Volume: 18 Suppl D Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Combinations; Fe	1986
A comparative study of ciprofloxacin and trimethoprim in the treatment of urinary tract infections in geriatric patients. The Journal of antimicrobial chemotherapy, 1986, Volume: 18 Suppl D Topics: Aged; Ciprofloxacin; Clinical Trials as Topic; Enterobacteriaceae Infections; Humans; Prospective St	1986
Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. Infection, 1986, Volume: 14 Suppl 4 Topics: Anti-Infective Agents; Ciprofloxacin; Clinical Trials as Topic; Double-Blind Method; Female; Humans;	1986
Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrobial agents and chemotherapy, 1987, Volume: 31, Issue:2 Topics: Adolescent; Adult; Ciprofloxacin; Drug Administration Schedule; Escherichia coli; Escherichia coli I	1987
Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cinoxacin; Ciprofloxacin; Clinical	1987
Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ciproflox	1987
Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials	1987
Oral ciprofloxacin in resistant urinary tract infections. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical	1987
Treatment of serious infections with intravenous ciprofloxacin. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Administration, Oral; Adult; Aged; Arthritis, Infectious; Bacterial Infections; Ciprofloxacin; Clini	1987
Ciprofloxacin: an update on clinical experience. The American journal of medicine, 1987, Apr-27, Volume: 82, Issue:4A Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Digestive System; Drug Resistance, Mi	1987

ciprofloxacin and Urinary Tract Infections